<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 39.96?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?subarticle pgen.1010300.r001?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">PLoS Genet</journal-id>
    <journal-id journal-id-type="iso-abbrev">PLoS Genet</journal-id>
    <journal-id journal-id-type="publisher-id">plos</journal-id>
    <journal-title-group>
      <journal-title>PLOS Genetics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1553-7390</issn>
    <issn pub-type="epub">1553-7404</issn>
    <publisher>
      <publisher-name>Public Library of Science</publisher-name>
      <publisher-loc>San Francisco, CA USA</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9612819</article-id>
    <article-id pub-id-type="pmid">36251721</article-id>
    <article-id pub-id-type="doi">10.1371/journal.pgen.1010300</article-id>
    <article-id pub-id-type="publisher-id">PGENETICS-D-22-00730</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Article</subject>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Gene Fusion</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Genomics</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Database and Informatics Methods</subject>
          <subj-group>
            <subject>Bioinformatics</subject>
            <subj-group>
              <subject>Sequence Analysis</subject>
              <subj-group>
                <subject>Sequence Alignment</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Oncology</subject>
          <subj-group>
            <subject>Cancers and Neoplasms</subject>
            <subj-group>
              <subject>Hematologic Cancers and Related Disorders</subject>
              <subj-group>
                <subject>Leukemia</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Hematology</subject>
          <subj-group>
            <subject>Hematologic Cancers and Related Disorders</subject>
            <subj-group>
              <subject>Leukemia</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Clinical Medicine</subject>
          <subj-group>
            <subject>Signs and Symptoms</subject>
            <subj-group>
              <subject>Lesions</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Gene Identification and Analysis</subject>
            <subj-group>
              <subject>Mutation Detection</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Organisms</subject>
          <subj-group>
            <subject>Eukaryota</subject>
            <subj-group>
              <subject>Animals</subject>
              <subj-group>
                <subject>Invertebrates</subject>
                <subj-group>
                  <subject>Cnidaria</subject>
                  <subj-group>
                    <subject>Jellyfish</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Zoology</subject>
          <subj-group>
            <subject>Animals</subject>
            <subj-group>
              <subject>Invertebrates</subject>
              <subj-group>
                <subject>Cnidaria</subject>
                <subj-group>
                  <subject>Jellyfish</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Gene Expression</subject>
          </subj-group>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)</article-title>
      <alt-title alt-title-type="running-head">RaScALL: Rapid screening of RNA-seq in acute lymphoblastic leukaemia</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Rehn</surname>
          <given-names>Jacqueline</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
        <role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff002" ref-type="aff">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6398-3046</contrib-id>
        <name>
          <surname>Mayoh</surname>
          <given-names>Chelsea</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
        <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff003" ref-type="aff">
          <sup>3</sup>
        </xref>
        <xref rid="aff004" ref-type="aff">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Heatley</surname>
          <given-names>Susan L</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff002" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="aff005" ref-type="aff">
          <sup>5</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>McClure</surname>
          <given-names>Barbara J</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff002" ref-type="aff">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1912-7602</contrib-id>
        <name>
          <surname>Eadie</surname>
          <given-names>Laura N</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff002" ref-type="aff">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Schutz</surname>
          <given-names>Caitlin</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yeung</surname>
          <given-names>David T</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff002" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="aff006" ref-type="aff">
          <sup>6</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Cowley</surname>
          <given-names>Mark J</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff003" ref-type="aff">
          <sup>3</sup>
        </xref>
        <xref rid="aff004" ref-type="aff">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6184-0925</contrib-id>
        <name>
          <surname>Breen</surname>
          <given-names>James</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff007" ref-type="aff">
          <sup>7</sup>
        </xref>
        <xref rid="aff008" ref-type="aff">
          <sup>8</sup>
        </xref>
        <xref rid="econtrib001" ref-type="author-notes">
          <sup>‡</sup>
        </xref>
        <xref rid="cor001" ref-type="corresp">*</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>White</surname>
          <given-names>Deborah L</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
        <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff002" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="aff005" ref-type="aff">
          <sup>5</sup>
        </xref>
        <xref rid="aff009" ref-type="aff">
          <sup>9</sup>
        </xref>
        <xref rid="aff010" ref-type="aff">
          <sup>10</sup>
        </xref>
        <xref rid="econtrib001" ref-type="author-notes">
          <sup>‡</sup>
        </xref>
      </contrib>
    </contrib-group>
    <aff id="aff001">
      <label>1</label>
      <addr-line>Blood Cancer Program, Precision Cancer Medicine Theme, South Australian Health &amp; Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia</addr-line>
    </aff>
    <aff id="aff002">
      <label>2</label>
      <addr-line>Faculty of Health and Medical Science, University of Adelaide, Adelaide, South Australia, Australia</addr-line>
    </aff>
    <aff id="aff003">
      <label>3</label>
      <addr-line>Children’s Cancer Institute, Kensington, New South Wales, Australia</addr-line>
    </aff>
    <aff id="aff004">
      <label>4</label>
      <addr-line>School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia</addr-line>
    </aff>
    <aff id="aff005">
      <label>5</label>
      <addr-line>Australian and New Zealand Children’s Oncology Group (ANZCHOG), Clayton, Victoria, Australia</addr-line>
    </aff>
    <aff id="aff006">
      <label>6</label>
      <addr-line>Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, South Australia, Australia</addr-line>
    </aff>
    <aff id="aff007">
      <label>7</label>
      <addr-line>Black Ochre Data Labs, Telethon Kids Institute, Adelaide, South Australia, Australia</addr-line>
    </aff>
    <aff id="aff008">
      <label>8</label>
      <addr-line>Australian National University, Canberra, Australian Capital Territory, Australia</addr-line>
    </aff>
    <aff id="aff009">
      <label>9</label>
      <addr-line>Australian Genomics Health Alliance (AGHA), Parkville, Victoria, Australia</addr-line>
    </aff>
    <aff id="aff010">
      <label>10</label>
      <addr-line>Faculty of Sciences, University of Adelaide, Adelaide, South Australia, Australia</addr-line>
    </aff>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Gartenhaus</surname>
          <given-names>Ronald B.</given-names>
        </name>
        <role>Editor</role>
        <xref rid="edit1" ref-type="aff"/>
      </contrib>
    </contrib-group>
    <aff id="edit1">
      <addr-line>VCU Massey Cancer Center, UNITED STATES</addr-line>
    </aff>
    <author-notes>
      <fn fn-type="COI-statement" id="coi001">
        <p>The authors have declared that no competing interests exist.</p>
      </fn>
      <fn fn-type="other" id="econtrib001">
        <p>‡ These authors are joint senior authors on this work.</p>
      </fn>
      <corresp id="cor001">* E-mail: <email>Jimmy.Breen@telethonkids.org.au</email></corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>17</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <volume>18</volume>
    <issue>10</issue>
    <elocation-id>e1010300</elocation-id>
    <history>
      <date date-type="received">
        <day>21</day>
        <month>6</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>22</day>
        <month>9</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2022 Rehn et al</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Rehn et al</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="pgen.1010300.pdf"/>
    <abstract>
      <p>RNA-sequencing (RNA-seq) efforts in acute lymphoblastic leukaemia (ALL) have identified numerous prognostically significant genomic alterations which can guide diagnostic risk stratification and treatment choices when detected early. However, integrating RNA-seq in a clinical setting requires rapid detection and accurate reporting of clinically relevant alterations. Here we present RaScALL, an implementation of the k-mer based variant detection tool <italic toggle="yes">km</italic>, capable of identifying more than 100 prognostically significant lesions observed in ALL, including gene fusions, single nucleotide variants and focal gene deletions. We compared genomic alterations detected by RaScALL and those reported by alignment-based <italic toggle="yes">de novo</italic> variant detection tools in a study cohort of 180 Australian patient samples. Results were validated using 100 patient samples from a published North American cohort. RaScALL demonstrated a high degree of accuracy for reporting subtype defining genomic alterations. Gene fusions, including difficult to detect fusions involving <italic toggle="yes">EPOR</italic> and <italic toggle="yes">DUX4</italic>, were accurately identified in 98% of reported cases in the study cohort (n = 164) and 95% of samples (n = 63) in the validation cohort. Pathogenic sequence variants were correctly identified in 75% of tested samples, including all cases involving subtype defining variants <italic toggle="yes">PAX5</italic> p.P80R (n = 12) and <italic toggle="yes">IKZF1</italic> p.N159Y (n = 4). Intragenic <italic toggle="yes">IKZF1</italic> deletions resulting in aberrant transcript isoforms were also detectable with 98% accuracy. Importantly, the median analysis time for detection of all targeted alterations averaged 22 minutes per sample, significantly shorter than standard alignment-based approaches. The application of RaScALL enables rapid identification and reporting of previously identified genomic alterations of known clinical relevance.</p>
    </abstract>
    <abstract abstract-type="summary">
      <title>Author summary</title>
      <p>Acute lymphoblastic leukaemia is a life-threatening malignancy characterised by various genomic alterations. RNA-sequencing (RNA-seq) is an effective method for identifying genomic lesions that drive patient disease, providing critical information about patient prognosis and treatment. However, analysis of RNA-seq data to identify clinically relevant genomic alterations is often time and resource intensive. Here, we present RaScALL, an integrated platform for rapid (Ra) screening (Sc) of RNA-seq data to identify genomic alterations of clinical significance in acute lymphoblastic leukaemia (ALL). RaScALL can detect more than 100 lesions of clinical importance from raw RNA-seq data, including gene fusions and sequence variants. A comparison of alterations detected by RaScALL and those reported by <italic toggle="yes">de novo</italic> variant detection tools confirmed that RaScALL is highly accurate and computationally efficient, with an average runtime of fewer than 30 minutes. Where RNA-seq data is available RaScALL provides rapid detection and reporting of prognostically significant lesions, which may ultimately assist with patient risk-stratification and therapeutic triage.</p>
    </abstract>
    <funding-group>
      <award-group id="award001">
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100017473</institution-id>
            <institution>Australian Genomics Health Alliance</institution>
          </institution-wrap>
        </funding-source>
        <award-id>1113531</award-id>
        <principal-award-recipient>
          <name>
            <surname>White</surname>
            <given-names>Deborah L</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award002">
        <funding-source>
          <institution>Beat Cancer</institution>
        </funding-source>
        <principal-award-recipient>
          <name>
            <surname>White</surname>
            <given-names>Deborah L</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award003">
        <funding-source>
          <institution>Leukemia Foundation</institution>
        </funding-source>
        <principal-award-recipient>
          <name>
            <surname>White</surname>
            <given-names>Deborah L</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award004">
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000925</institution-id>
            <institution>National Health and Medical Research Council</institution>
          </institution-wrap>
        </funding-source>
        <award-id>1160833</award-id>
        <principal-award-recipient>
          <name>
            <surname>White</surname>
            <given-names>Deborah L</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award005">
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000925</institution-id>
            <institution>National Health and Medical Research Council</institution>
          </institution-wrap>
        </funding-source>
        <award-id>1146253</award-id>
        <principal-award-recipient>
          <name>
            <surname>Yeung</surname>
            <given-names>David T</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award006">
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100018675</institution-id>
            <institution>Kids' Cancer Project</institution>
          </institution-wrap>
        </funding-source>
        <principal-award-recipient>
          <name>
            <surname>Heatley</surname>
            <given-names>Susan L</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award007">
        <funding-source>
          <institution>Peter Nelson Leukaemia Research Fellow</institution>
        </funding-source>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1912-7602</contrib-id>
          <name>
            <surname>Eadie</surname>
            <given-names>Laura N</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award008">
        <funding-source>
          <institution>Australian Research Training Program</institution>
        </funding-source>
        <principal-award-recipient>
          <name>
            <surname>Rehn</surname>
            <given-names>Jacqueline</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award009">
        <funding-source>
          <institution>Australian Research Training Program</institution>
        </funding-source>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6398-3046</contrib-id>
          <name>
            <surname>Mayoh</surname>
            <given-names>Chelsea</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <funding-statement>This work was supported by funding from the Australian Genomics Health Alliance (AGHA) (1113531 to DLW), Beat Cancer (DLW, <ext-link xlink:href="http://www.cancersa.org.au" ext-link-type="uri">www.cancersa.org.au</ext-link>), and the Leukaemia Foundation (DLW, <ext-link xlink:href="http://www.leukaemia.org.au" ext-link-type="uri">www.leukaemia.org.au</ext-link>). DLW is an NHMRC R.D. Wright II Fellow (1160833) and a Beat Cancer Principal Research Fellow. DTY is an NHMRC Early Career Fellow (1146253). SLH is The Kids’ Cancer Project Fellow (<ext-link xlink:href="http://www.thekidscancerproject.org.au" ext-link-type="uri">www.thekidscancerproject.org.au</ext-link>). LNE is the Peter Nelson Leukaemia Research Fellow (<ext-link xlink:href="http://www.cancersa.org.au" ext-link-type="uri">www.cancersa.org.au</ext-link>). JR and CM were supported by funding from the Australian Research Training Program (RTP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
    </funding-group>
    <counts>
      <fig-count count="4"/>
      <table-count count="2"/>
      <page-count count="23"/>
    </counts>
    <custom-meta-group>
      <custom-meta>
        <meta-name>PLOS Publication Stage</meta-name>
        <meta-value>vor-update-to-uncorrected-proof</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>Publication Update</meta-name>
        <meta-value>2022-10-27</meta-value>
      </custom-meta>
      <custom-meta id="data-availability">
        <meta-name>Data Availability</meta-name>
        <meta-value>Raw FASTQ files for ALL samples in the study cohort are available from Genome-phenome Archive (EGAS00001006460). BAM files for the validation cohort containing 100 ALL samples are available from the European Genome-phenome Archive (accession numbers EGAD00001004461 and EGAD00001004463). Target sequences described in this study can be accessed via figshare (<ext-link xlink:href="https://doi.org/10.25909/19372559.v1" ext-link-type="uri">https://doi.org/10.25909/19372559.v1</ext-link>). Code and additional scripts for running RaScALL are available from the GitHub repository (<ext-link xlink:href="https://github.com/j-rehn/RaScALL" ext-link-type="uri">https://github.com/j-rehn/RaScALL</ext-link>).</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
  <notes>
    <title>Data Availability</title>
    <p>Raw FASTQ files for ALL samples in the study cohort are available from Genome-phenome Archive (EGAS00001006460). BAM files for the validation cohort containing 100 ALL samples are available from the European Genome-phenome Archive (accession numbers EGAD00001004461 and EGAD00001004463). Target sequences described in this study can be accessed via figshare (<ext-link xlink:href="https://doi.org/10.25909/19372559.v1" ext-link-type="uri">https://doi.org/10.25909/19372559.v1</ext-link>). Code and additional scripts for running RaScALL are available from the GitHub repository (<ext-link xlink:href="https://github.com/j-rehn/RaScALL" ext-link-type="uri">https://github.com/j-rehn/RaScALL</ext-link>).</p>
  </notes>
</front>
<body>
  <sec sec-type="intro" id="sec001">
    <title>Introduction</title>
    <p>Acute lymphoblastic leukaemia (ALL) is a life-threatening haematological malignancy characterised by a wide variety of genomic alterations. It is the most common childhood cancer and accounts for 15–25% of adult acute leukaemia [<xref rid="pgen.1010300.ref001" ref-type="bibr">1</xref>]. Although the introduction of risk-adapted therapy has significantly improved treatment outcomes, particularly in paediatric cohorts, relapsed and refractory disease remains lethal. High-risk genomic lesions are disproportionately frequent in adolescent and adult patients, contributing to higher relapse rates and poorer overall survival [<xref rid="pgen.1010300.ref002" ref-type="bibr">2</xref>]. Timely and accurate identification of genomic variants involved in disease pathogenesis is therefore essential both for patient risk stratification and the identification of individuals who may benefit from precision medicine approaches [<xref rid="pgen.1010300.ref003" ref-type="bibr">3</xref>].</p>
    <p>In the past decade, next-generation sequencing (NGS) of large patient cohorts has greatly expanded our understanding of the genomic alterations driving leukaemia progression and identified additional molecular targets amenable to targeted therapy [<xref rid="pgen.1010300.ref004" ref-type="bibr">4</xref>–<xref rid="pgen.1010300.ref006" ref-type="bibr">6</xref>]. This includes the identification of a variety of gene fusions, many of which are cytogenetically cryptic [<xref rid="pgen.1010300.ref003" ref-type="bibr">3</xref>,<xref rid="pgen.1010300.ref007" ref-type="bibr">7</xref>]. These gene fusions often result in chimeric transcripts consisting of exons from two different genes, with resultant chimeric proteins driving leukemogenesis [<xref rid="pgen.1010300.ref002" ref-type="bibr">2</xref>]. Several of these fusions result in the activation of kinase signalling, some of which may be abrogated by currently available therapies [<xref rid="pgen.1010300.ref008" ref-type="bibr">8</xref>,<xref rid="pgen.1010300.ref009" ref-type="bibr">9</xref>]. Alternatively, a gene fusion can result in altered expression of cytokine receptors [<xref rid="pgen.1010300.ref010" ref-type="bibr">10</xref>–<xref rid="pgen.1010300.ref012" ref-type="bibr">12</xref>] or transcription factors [<xref rid="pgen.1010300.ref013" ref-type="bibr">13</xref>,<xref rid="pgen.1010300.ref014" ref-type="bibr">14</xref>] due to the placement of these genes under alternate transcriptional regulation [<xref rid="pgen.1010300.ref012" ref-type="bibr">12</xref>–<xref rid="pgen.1010300.ref014" ref-type="bibr">14</xref>]. Each of these genomic alterations is associated with distinct gene expression and risk profiles [<xref rid="pgen.1010300.ref004" ref-type="bibr">4</xref>–<xref rid="pgen.1010300.ref006" ref-type="bibr">6</xref>].</p>
    <p>Missense mutations resulting in loss of function of key lymphoid transcription factors have also been detected and represent gene distinct expression and risk profiles [<xref rid="pgen.1010300.ref004" ref-type="bibr">4</xref>,<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>]. Furthermore, studies have revealed several cooperating mutations that are either associated with relapse or indicative of high-risk disease. For example, single nucleotide variants (SNVs) affecting genes of the RAS pathway have been associated with relapsed ALL [<xref rid="pgen.1010300.ref015" ref-type="bibr">15</xref>,<xref rid="pgen.1010300.ref016" ref-type="bibr">16</xref>]. Activating mutations of <italic toggle="yes">JAK2</italic> and <italic toggle="yes">CRLF2</italic> occurring concurrently in patients with overexpression of CRLF2 promote JAK-STAT activation and high-risk disease [<xref rid="pgen.1010300.ref010" ref-type="bibr">10</xref>,<xref rid="pgen.1010300.ref017" ref-type="bibr">17</xref>,<xref rid="pgen.1010300.ref018" ref-type="bibr">18</xref>]. Focal deletions of the lymphoid transcription factor IKAROS <italic toggle="yes">(IKZF1)</italic> and other transcription factors critical to B-cell development are independent prognostic factors indicative of poor outcomes [<xref rid="pgen.1010300.ref010" ref-type="bibr">10</xref>,<xref rid="pgen.1010300.ref019" ref-type="bibr">19</xref>–<xref rid="pgen.1010300.ref021" ref-type="bibr">21</xref>]. Early detection of cooperating mutations indicative of high-risk disease is likewise essential for the identification of patients who may benefit from intensified therapy.</p>
    <p>These advances have led to an increase in NGS, particularly RNA-sequencing (RNA-seq), for identifying genomic lesions indicative of disease risk. However, full implementation of NGS in a clinical setting depends upon the rapid and accurate identification of clinically relevant variants [<xref rid="pgen.1010300.ref007" ref-type="bibr">7</xref>,<xref rid="pgen.1010300.ref022" ref-type="bibr">22</xref>]. Currently, there is no standard, ‘Best Practice’ RNA-seq diagnostic pipeline for the detection of genomic variants [<xref rid="pgen.1010300.ref023" ref-type="bibr">23</xref>], with independent research groups developing their own in-house bioinformatic pipelines for analysis [<xref rid="pgen.1010300.ref004" ref-type="bibr">4</xref>–<xref rid="pgen.1010300.ref006" ref-type="bibr">6</xref>,<xref rid="pgen.1010300.ref024" ref-type="bibr">24</xref>]. Multiple programs exist for <italic toggle="yes">de novo</italic> detection of sequence variants and gene fusions from RNA-seq data but vary in their sensitivity to detect clinically relevant lesions [<xref rid="pgen.1010300.ref023" ref-type="bibr">23</xref>,<xref rid="pgen.1010300.ref025" ref-type="bibr">25</xref>–<xref rid="pgen.1010300.ref027" ref-type="bibr">27</xref>]. Furthermore, these programs report large numbers of expressed variants or chimeric transcripts, many of which are either false positives or do not represent clinically relevant alterations. Consequently, extensive knowledge-based filtering and manual curation are required to identify alterations for clinical reporting [<xref rid="pgen.1010300.ref025" ref-type="bibr">25</xref>].</p>
    <p>Recently, a new command line tool for targeted detection of genomic variants was developed, which relies on a k-mer based or pseudo-alignment approach rather than the direct mapping of reads to a reference genome. This application, <italic toggle="yes">km</italic> [<xref rid="pgen.1010300.ref028" ref-type="bibr">28</xref>], differs from standard analysis by limiting the search space to a set of target sequences representing known genomic alterations. Raw RNA-seq data, decomposed into substrings or k-mers, is assembled across target sequences by an algorithm that identifies diverging paths indicative of substitutions, insertions, or deletions. Pseudo-alignment is incredibly memory and computationally efficient, leading to a considerable reduction in analysis time [<xref rid="pgen.1010300.ref028" ref-type="bibr">28</xref>]. However, the application of <italic toggle="yes">km</italic> to ALL patient samples requires the development of target sequences representing disease-specific lesions and an evaluation of performance against more commonly employed <italic toggle="yes">de novo</italic> variant detection tools.</p>
    <p>Here we present RaScALL, an integrated pipeline utilising <italic toggle="yes">km</italic> for rapid (Ra) screening (Sc) of RNA-seq data for clinically relevant variants in patients with ALL. RaScALL contains target sequences for the detection of more than 100 clinically relevant genomic alterations, including 75 distinct gene fusions, with the functionality to generate custom target sequences to identify novel variants. We demonstrate the ability of RaScALL to detect subtype defining genomic alterations rapidly and accurately, including gene fusions involving the <italic toggle="yes">IGH</italic> locus that are frequently under-reported by alignment-based fusion calling tools. We also successfully identify cooperating mutations, including single nucleotide variants (SNVs) and intragenic <italic toggle="yes">IKZF1</italic> deletions, contributing to patient prognosis.</p>
  </sec>
  <sec sec-type="results" id="sec002">
    <title>Results</title>
    <sec id="sec003">
      <title>Study cohort overview</title>
      <p>To investigate the applicability of targeted methods for detecting disease-defining genomic alterations a study cohort consisting of 180 patient samples representing common prognostically significant genomic lesions was employed. A separate validation cohort of 100 B-ALL samples representing a broader range of B-ALL subtypes was utilised to verify these results. The study cohort including B-ALL (n = 160), T-ALL (n = 18), acute undifferentiated leukaemia (n = 1) and acute bi-phenotypic leukaemia (n = 1) was selected, from a larger pool of samples referred to the South Australian Health and Medical Research Institute for genomic analysis (<xref rid="pgen.1010300.s001" ref-type="supplementary-material">S1 Table</xref>). Informed consents were given under HREC approved clinical trial protocols. For this study cohort, subtype defining gene fusions and other recurrently observed genomic alterations were initially identified by a <italic toggle="yes">de novo</italic> variant calling and fusion detection pipeline. A ‘Best Practice’ GATK RNA-seq variant calling workflow [<xref rid="pgen.1010300.ref029" ref-type="bibr">29</xref>] was applied to raw patient RNA-seq datasets, relying on haplotype caller for identification of SNVs and Insertion/Deletions (InDels).</p>
      <p>Gene fusion detection was performed using four fusion calling algorithms: <italic toggle="yes">FusionCatcher</italic> [<xref rid="pgen.1010300.ref030" ref-type="bibr">30</xref>], <italic toggle="yes">SOAPfuse</italic> [<xref rid="pgen.1010300.ref031" ref-type="bibr">31</xref>], <italic toggle="yes">JAFFA</italic> [<xref rid="pgen.1010300.ref032" ref-type="bibr">32</xref>] and <italic toggle="yes">arriba</italic> [<xref rid="pgen.1010300.ref023" ref-type="bibr">23</xref>]. Apart from <italic toggle="yes">IGH</italic> rearrangements (<italic toggle="yes">IGH</italic>r), consensus between two or more algorithms was required for reporting clinically relevant gene fusions. Rearrangements of <italic toggle="yes">IGH</italic> are frequently under-reported by many fusion calling algorithms due to poor alignment across the <italic toggle="yes">IGH</italic> region of the genome [<xref rid="pgen.1010300.ref022" ref-type="bibr">22</xref>,<xref rid="pgen.1010300.ref025" ref-type="bibr">25</xref>], making consensus between callers more difficult in these instances. Fluorescence <italic toggle="yes">in situ</italic> hybridisation (FISH) was therefore utilised to confirm <italic toggle="yes">IGH-CRLF2</italic> gene fusions (<xref rid="pgen.1010300.s001" ref-type="supplementary-material">S1 Table</xref>) while <italic toggle="yes">IGH-EPOR</italic> alterations were verified by visual inspection of the BAM file. Patients with <italic toggle="yes">IGH-DUX4</italic> rearrangements were identified via gene expression profiling (<xref rid="pgen.1010300.s007" ref-type="supplementary-material">S1 Fig</xref>). All patient samples were sequenced to high coverage (mean 70M PE reads). A minimal set of three samples (<italic toggle="yes">ETV6-ABL1</italic>, n = 2) representing each subtype defining gene fusion or SNV was included for testing and development of RaScALL, with additional samples selected to maximise common genetic subtypes along with <italic toggle="yes">IGH-CRLF2</italic> and <italic toggle="yes">IGH-DUX4</italic> alterations that are difficult to identify by alignment-based tools. The reported genomic alteration, along with age and subtype classification, is represented in <xref rid="pgen.1010300.g001" ref-type="fig">Fig 1</xref>.</p>
      <fig position="float" id="pgen.1010300.g001">
        <object-id pub-id-type="doi">10.1371/journal.pgen.1010300.g001</object-id>
        <label>Fig 1</label>
        <caption>
          <title>Genomic alterations for patients within the study cohort.</title>
          <p>Reported genomic alterations for 180 ALL samples analysed by RNA-seq, including 160 B-ALL patient samples (left panel), 18 patients samples classified as T-ALL (right panel), and two samples with acute undifferentiated leukaemia or acute bi-phenotypic leukaemia (middle panel). Each column represents a single patient. Patients were classified into a recognised subtype based on the detected driver mutation. For each patient, the deletion status of <italic toggle="yes">IKZF1</italic>, as reported by multiplex ligation-dependent probe amplification, as well as patient diagnosis, age group and sample timepoint are shown and coloured according to the key. Clinically relevant gene fusions detected with RNA-seq are indicated in the middle panel and shown in dark grey. The bottom panel indicates samples for which known pathogenic SNVs were detected by GATK Haplotype caller (shown in dark grey).</p>
        </caption>
        <graphic xlink:href="pgen.1010300.g001" position="float"/>
      </fig>
    </sec>
    <sec id="sec004">
      <title>Overview of RaScALL</title>
      <p>RaScALL is an implementation of <italic toggle="yes">km</italic> for rapid screening of raw RNA-seq data to identify a predefined list of clinically relevant genomic alterations in ALL. Variant detection requires target sequences representing known fusion breakpoints or regions surrounding an SNV or InDel of interest. Target sequences of 62b length were generated for 25 gene fusions involving exon-exon breakpoint sequences affecting patients in the study cohort (<xref rid="pgen.1010300.s002" ref-type="supplementary-material">S2 Table</xref>). For <italic toggle="yes">IGH-EPOR</italic> and <italic toggle="yes">IGH-CRLF2</italic> gene fusions, with highly variable breakpoint locations, targets represented sequence upstream of commonly reported <italic toggle="yes">CRLF2/EPOR</italic> breakpoints combined with sequence from all <italic toggle="yes">IGK</italic>, <italic toggle="yes">IGHJ</italic> and <italic toggle="yes">IGHD</italic> alleles. Rearrangements of <italic toggle="yes">DUX4</italic> (<italic toggle="yes">DUX4</italic>r) likewise have highly variable breakpoint locations but result in high-level expression of <italic toggle="yes">DUX4</italic>, which is otherwise absent in leukaemic and non-leukaemic lymphocytes. Thus, targets representing the <italic toggle="yes">DUX4</italic> mRNA transcript were created for the detection of <italic toggle="yes">DUX4</italic> expression as an indicator of <italic toggle="yes">DUX4</italic>r (see <xref rid="sec012" ref-type="sec">Materials and Methods</xref> for details). Additional targets consisting of reference sequences surrounding 16 clinically relevant SNVs were also generated (<xref rid="pgen.1010300.s002" ref-type="supplementary-material">S2 Table</xref>).</p>
      <p>To perform variant detection with RaScALL, raw FASTQ files from patient samples are indexed by <italic toggle="yes">jellyfish</italic> v2.2.6 [<xref rid="pgen.1010300.ref033" ref-type="bibr">33</xref>] to generate a k-mer count table (k = 31) and passed to <italic toggle="yes">km</italic> [<xref rid="pgen.1010300.ref028" ref-type="bibr">28</xref>] for assembly of k-mers across the provided target sequences. The output is then filtered, collated, and annotated using a meta-caller R script to generate a final output file containing reportable genomic alterations. Only instances where each k-mer in the target sequence was identified were considered positive identification of the fusion or sequence variant. A command line utility to generate custom targets for gene fusions, SNVs and InDels is also provided (<xref rid="pgen.1010300.g002" ref-type="fig">Fig 2A</xref>).</p>
      <fig position="float" id="pgen.1010300.g002">
        <object-id pub-id-type="doi">10.1371/journal.pgen.1010300.g002</object-id>
        <label>Fig 2</label>
        <caption>
          <title>Detection of subtype-defining gene fusions by RaScALL.</title>
          <p>(A) RaScALL workflow. RaScALL is a self-contained command line utility for detecting ALL specific variants. RNA-seq data in the form of raw FASTQ files are indexed by <italic toggle="yes">jellyfish</italic> to generate a k-mer count table. Next, gene fusions, focal gene deletions, SNVs and InDels are detected with <italic toggle="yes">km</italic> for genomic regions specified in the target set and the output is filtered to provide a single file with clinically relevant alterations for reporting. (B) Schematic representation of gene fusion target sequences (top panel) and causes of false-negative reports. A false negative occur when the patient possesses an alternate breakpoint lacking one of the exons in the gene fusion target (middle panel), or due to the presence of a SNP preventing an exact match of the first or final k-mer in the target sequence (bottom panel). (C) Frequency of detection of non-<italic toggle="yes">IGH</italic> gene fusions by RaScALL in the study cohort. Blue bar indicating that RaScALL detected the same gene fusion reported by two or more alignment-based fusion calling algorithms and a single sample in pink for which RaScALL failed to detect a clinically reported gene fusion. (D) Frequency of <italic toggle="yes">IGH-CRLF2</italic>, <italic toggle="yes">IGH-EPOR</italic> or <italic toggle="yes">DUX4</italic>r in the study cohort as determined by FISH for <italic toggle="yes">IGH-CRLF2</italic> or gene expression profiling (GEP) for <italic toggle="yes">DUX4</italic>r (grey). Coloured bars indicate the number of samples for which RaScALL (purple) or one of 4 alignment-based fusion calling algorithms detected the rearrangement in the given patient sample.</p>
        </caption>
        <graphic xlink:href="pgen.1010300.g002" position="float"/>
      </fig>
    </sec>
    <sec id="sec005">
      <title>Memory and run-time evaluation</title>
      <p>Speed and computational resource requirements are important considerations for bioinformatic analysis in a clinical setting. Variant detection with RaScALL is a two-step process. RNA-seq data is initially indexed with the command line tool <italic toggle="yes">jellyfish</italic> [<xref rid="pgen.1010300.ref033" ref-type="bibr">33</xref>] to generate a k-mer count table for the patient. <italic toggle="yes">Km</italic> [<xref rid="pgen.1010300.ref028" ref-type="bibr">28</xref>] then utilises the count table to assemble the target sequences from overlapping k-mers and identify divergent paths representing variants. Both steps contribute to the overall memory requirements and analysis time and were evaluated to assess the effects of sequencing length and depth on runtime. Maximum memory requirements for indexing were dependent on the size of the RNA-seq dataset, read length and sequencing depth, consistent with previous benchmarking studies [<xref rid="pgen.1010300.ref034" ref-type="bibr">34</xref>]. Memory requirements increased from 4.7GB for datasets with 75b length PE reads and depth of 40 million reads up to 17.8G for datasets involving 150bp length and 80 million reads (<xref rid="pgen.1010300.s003" ref-type="supplementary-material">S3 Table</xref>). Runtime likewise increased with the size of the dataset to process but could be minimised by increasing the number of available threads. When performed with 12 threads, on data with 75b read length and read depth of 80M, the mean runtime was 6.5 minutes (<xref rid="pgen.1010300.s003" ref-type="supplementary-material">S3 Table</xref>).</p>
      <p>Memory requirements and runtimes for variant detection with <italic toggle="yes">km</italic> are much smaller than the indexing step, although do increase with the increasing size of the RNA-seq data (<xref rid="pgen.1010300.t001" ref-type="table">Table 1</xref>). Runtime for detection of <italic toggle="yes">IGH-CRLF2 and IGH-EPOR</italic> gene fusions was considerably longer than detection of other genomic alterations, averaging 8.7 minutes for datasets of 50-70M reads, compared with less than 30 seconds for all other targets. Targets for detection of <italic toggle="yes">IGH-CRLF2</italic> and <italic toggle="yes">IGH-EPOR</italic> represent sequences from regions placed in proximity when a rearrangement occurs rather than the exact sequence generated by fusions producing exon-exon breakpoints. The large diversity of sequence and high-level expression associated with the <italic toggle="yes">IGH</italic> locus can account for this additional analysis time. Overall analysis time for sample indexing and assessment of targeted variants for the study cohort averaged 16.8 minutes. Based on a benchmarking assessment utilising 9 samples, only <italic toggle="yes">arriba</italic> demonstrated comparable speed (mean 13.5 minutes) with run times increasing to 14.5 hours for <italic toggle="yes">SOAPfuse</italic> (<xref rid="pgen.1010300.s008" ref-type="supplementary-material">S2 Fig</xref>). Importantly, the speed of <italic toggle="yes">arriba</italic> was dependent on significantly higher memory utilisation than RaScALL (mean 34.4GB vs 10.8GB). While we recognise that this is not a fair comparison given that RaScALL can only detect a limited repertoire of gene fusions compared to arriba, the high speed and lower memory utilisation represent a significant saving in bioinformatic costs in a cloud computing environment where pricing is dependent on both variables [<xref rid="pgen.1010300.ref035" ref-type="bibr">35</xref>].</p>
      <table-wrap position="float" id="pgen.1010300.t001">
        <object-id pub-id-type="doi">10.1371/journal.pgen.1010300.t001</object-id>
        <label>Table 1</label>
        <caption>
          <title>Memory and runtime requirements for variant detection from previously indexed RNA-seq data.</title>
          <p>Values represent mean time and memory for samples of specified sequencing depth.</p>
        </caption>
        <alternatives>
          <graphic xlink:href="pgen.1010300.t001" id="pgen.1010300.t001g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="2" colspan="1">Target set</th>
                <th align="center" rowspan="2" colspan="1">No. target sequences</th>
                <th align="center" rowspan="2" colspan="1">Target length</th>
                <th align="center" colspan="3" rowspan="1"><italic toggle="yes">Km</italic> run time (s)</th>
                <th align="center" colspan="3" rowspan="1">Peak RSS (GB)</th>
              </tr>
              <tr>
                <th align="center" rowspan="1" colspan="1">Low (&lt;50M)</th>
                <th align="center" rowspan="1" colspan="1">Medium (50-80M)</th>
                <th align="center" rowspan="1" colspan="1">High (80+M)</th>
                <th align="center" rowspan="1" colspan="1">Low (&lt;50M)</th>
                <th align="center" rowspan="1" colspan="1">Medium (50-80M)</th>
                <th align="center" rowspan="1" colspan="1">High (80+M)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">SNV</td>
                <td align="left" rowspan="1" colspan="1">14</td>
                <td align="left" rowspan="1" colspan="1">69–72</td>
                <td align="left" rowspan="1" colspan="1">0.15</td>
                <td align="left" rowspan="1" colspan="1">0.15</td>
                <td align="left" rowspan="1" colspan="1">0.17</td>
                <td align="left" rowspan="1" colspan="1">0.04</td>
                <td align="left" rowspan="1" colspan="1">0.05</td>
                <td align="left" rowspan="1" colspan="1">0.05</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">DUX4</td>
                <td align="left" rowspan="1" colspan="1">12</td>
                <td align="left" rowspan="1" colspan="1">70</td>
                <td align="left" rowspan="1" colspan="1">0.08</td>
                <td align="left" rowspan="1" colspan="1">0.15</td>
                <td align="left" rowspan="1" colspan="1">0.18</td>
                <td align="left" rowspan="1" colspan="1">0.03</td>
                <td align="left" rowspan="1" colspan="1">0.05</td>
                <td align="left" rowspan="1" colspan="1">0.05</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic toggle="yes">IKZF1</italic> deletion</td>
                <td align="left" rowspan="1" colspan="1">3</td>
                <td align="left" rowspan="1" colspan="1">62</td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>1.67</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">2.71</td>
                <td align="left" rowspan="1" colspan="1">2.84</td>
                <td align="left" rowspan="1" colspan="1">0.10</td>
                <td align="left" rowspan="1" colspan="1">0.13</td>
                <td align="left" rowspan="1" colspan="1">0.12</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Fusion</td>
                <td align="left" rowspan="1" colspan="1">67</td>
                <td align="left" rowspan="1" colspan="1">62</td>
                <td align="left" rowspan="1" colspan="1">4.73</td>
                <td align="left" rowspan="1" colspan="1">5.09</td>
                <td align="left" rowspan="1" colspan="1">6.70</td>
                <td align="left" rowspan="1" colspan="1">0.90</td>
                <td align="left" rowspan="1" colspan="1">0.76</td>
                <td align="left" rowspan="1" colspan="1">0.88</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">IGH-EPOR</italic>
                </td>
                <td align="left" rowspan="1" colspan="1">1656</td>
                <td align="left" rowspan="1" colspan="1">64–68</td>
                <td align="left" rowspan="1" colspan="1">13.88</td>
                <td align="left" rowspan="1" colspan="1">27.57</td>
                <td align="left" rowspan="1" colspan="1">32.91</td>
                <td align="left" rowspan="1" colspan="1">0.87</td>
                <td align="left" rowspan="1" colspan="1">0.98</td>
                <td align="left" rowspan="1" colspan="1">1.08</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">IGH-CRLF2</italic>
                </td>
                <td align="left" rowspan="1" colspan="1">525</td>
                <td align="left" rowspan="1" colspan="1">81–100</td>
                <td align="left" rowspan="1" colspan="1">400.26</td>
                <td align="left" rowspan="1" colspan="1">342.92</td>
                <td align="left" rowspan="1" colspan="1">505.12</td>
                <td align="left" rowspan="1" colspan="1">2.66</td>
                <td align="left" rowspan="1" colspan="1">1.08</td>
                <td align="left" rowspan="1" colspan="1">3.57</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
    </sec>
    <sec id="sec006">
      <title>RaScALL accurately detects subtype defining gene fusions</title>
      <p>RaScALL was applied to samples in the study cohort and alterations detected by RaScALL were then compared to the reported gene fusions for the patient based on the <italic toggle="yes">de novo</italic> bioinformatic analysis using a standard reference genome alignment approach (<xref rid="pgen.1010300.s004" ref-type="supplementary-material">S4 Table</xref>). There were 127 non-<italic toggle="yes">IGH</italic>r subtype defining gene fusions, of which 126 were detected with RaScALL (<xref rid="pgen.1010300.g002" ref-type="fig">Fig 2C</xref>). The reciprocal gene fusion (<italic toggle="yes">ABL1-BCR</italic>, <italic toggle="yes">AFF1-KMT2A</italic>, <italic toggle="yes">MLLT10-PICALM</italic>, <italic toggle="yes">MLLT10-DDX3X</italic> and <italic toggle="yes">ZNF384-EP300</italic>) was also identified for 49 of 50 patient samples (<xref rid="pgen.1010300.s004" ref-type="supplementary-material">S4 Table</xref>). The false negative result, in which RaScALL failed to identify a non-<italic toggle="yes">IGH</italic>r gene fusion reported by all alignment-based fusion calling algorithms, was for a patient possessing an <italic toggle="yes">ETV6-RUNX1</italic> translocation with a novel breakpoint lacking the first k-mer of the target sequence provided (<xref rid="pgen.1010300.g002" ref-type="fig">Fig 2B</xref> middle panel). The generation of an additional target with this uncommon breakpoint resulted in the correct identification of the fusion. No fusions were reported for the 16 cases in the study cohort identified as fusion negative using the <italic toggle="yes">de novo</italic> variant detection pipelines (<xref rid="pgen.1010300.s004" ref-type="supplementary-material">S4 Table</xref>).</p>
      <p>Clinically relevant <italic toggle="yes">IGH</italic>r are detected less reliably from RNA-seq than other gene fusions [<xref rid="pgen.1010300.ref023" ref-type="bibr">23</xref>,<xref rid="pgen.1010300.ref025" ref-type="bibr">25</xref>] and were thus considered separately. <italic toggle="yes">IGH-CRLF2</italic> was detected by RaScALL in 16 of 17 cases for which the translocation had been identified by FISH with no false positive results (<xref rid="pgen.1010300.g002" ref-type="fig">Fig 2D</xref>). For the remaining sample, the <italic toggle="yes">IGH-CRLF2</italic> fusion breakpoint occurred outside the range of targets generated. <italic toggle="yes">IGH-EPOR</italic> was detected in all 3 samples carrying this genomic alteration. Multiple targets representing the <italic toggle="yes">DUX4</italic> mRNA transcript were detected in all 17 samples previously identified as <italic toggle="yes">DUX4</italic>r by gene expression profiling, including two samples where a <italic toggle="yes">DUX4</italic> fusion was not identified by any alignment-based fusion calling algorithm (<xref rid="pgen.1010300.g002" ref-type="fig">Fig 2D</xref>). Mean minimum k-mer coverage across targets for these samples ranged from 76–2690 k-mers with all samples indicating the presence of 6–9 DUX4 targets. Additionally, there were 8 non-<italic toggle="yes">DUX4</italic>r samples for which 1 or 2 targets could be assembled, but all reported mean minimum coverage of 2–4 kmers (<xref rid="pgen.1010300.s009" ref-type="supplementary-material">S3 Fig</xref>). Application of filters to exclude calls where fewer than 4 DUX4 targets were detected with a minimum of 10 k-mers effectively excluded all potential false-positive results. Overall, detection rate of clinically relevant gene fusions by RaScALL was comparable with the most sensitive alignment-based caller FusionCatcher (<xref rid="pgen.1010300.s010" ref-type="supplementary-material">S4 Fig</xref>).</p>
    </sec>
    <sec id="sec007">
      <title>Detection of <italic toggle="yes">IKZF1</italic> deletions</title>
      <p>Deletion of <italic toggle="yes">IKZF1</italic>, a transcription factor required for lymphoid development, has been identified as an independent prognostic indicator of high-risk disease [<xref rid="pgen.1010300.ref020" ref-type="bibr">20</xref>,<xref rid="pgen.1010300.ref021" ref-type="bibr">21</xref>]. Two commonly observed intragenic <italic toggle="yes">IKZF1</italic> deletions, exon 2–7 and exon 4–7, result in aberrantly spliced transcripts of <italic toggle="yes">IKZF1</italic> leading to haploinsufficiency of the transcription factor or production of a dominant-negative isoform ik6 [<xref rid="pgen.1010300.ref036" ref-type="bibr">36</xref>,<xref rid="pgen.1010300.ref037" ref-type="bibr">37</xref>]. Deletions in <italic toggle="yes">IKZF1</italic> are typically identified through DNA sequencing techniques, single nucleotide polymorphism microarrays (SNParray) [<xref rid="pgen.1010300.ref036" ref-type="bibr">36</xref>], or through low-throughput targeted detection approaches such as multiplex ligation-dependent probe amplification (MLPA) [<xref rid="pgen.1010300.ref038" ref-type="bibr">38</xref>,<xref rid="pgen.1010300.ref039" ref-type="bibr">39</xref>]. Intragenic deletions resulting in aberrantly spliced transcripts can however be detected from RNA-seq data [<xref rid="pgen.1010300.ref040" ref-type="bibr">40</xref>].</p>
      <p>Within the study cohort, <italic toggle="yes">IKZF1</italic> deletions were identified by RaScALL using targets representing aberrantly spliced transcripts. Of the 98 samples with available MLPA data, transcripts supporting an exon 4–7 or exon 2–7 <italic toggle="yes">IKZF1</italic> deletion were correctly detected in 27 patient samples. A target seqeunce for the detection of exon 2–3 deletions was also generated, but this deletion was not present in any of the samples analysed by MLPA (<xref rid="pgen.1010300.s004" ref-type="supplementary-material">S4 Table</xref>). There were 9 discordant results in which RaScALL indicated the presence of transcripts representing an <italic toggle="yes">IKZF1</italic> deletion with limited supporting k-mers that were not supported by MLPA (<xref rid="pgen.1010300.g003" ref-type="fig">Fig 3A</xref>). These likely represent low numbers of aberrantly spliced <italic toggle="yes">IKZF1</italic> transcripts and not true deletions. Application of a filter to exclude <italic toggle="yes">IKZF1</italic> deletion predictions with a minimum k-mer coverage of less than 10, resulted in the condordant detection of 24 <italic toggle="yes">IKZF1</italic> deletions and one discordant exon 4–7 <italic toggle="yes">IKZF1</italic> deletion, occurring in a Ph+ALL hyperdiploid patient. Additional <italic toggle="yes">IKZF1</italic> deletions, including whole gene deletions and deletions of exons 4–8 went undetected (<xref rid="pgen.1010300.g003" ref-type="fig">Fig 3B</xref> and <xref rid="pgen.1010300.s004" ref-type="supplementary-material">S4 Table</xref>). Deletions of <italic toggle="yes">IKZF1</italic> were detected by RaScALL in an additional 25 samples lacking MLPA (<xref rid="pgen.1010300.s004" ref-type="supplementary-material">S4 Table</xref>). While these deletions could not be verified, all occurred in patient samples representing subtypes commonly associated with <italic toggle="yes">IKZF1</italic> deletion.</p>
      <fig position="float" id="pgen.1010300.g003">
        <object-id pub-id-type="doi">10.1371/journal.pgen.1010300.g003</object-id>
        <label>Fig 3</label>
        <caption>
          <title>Detection of <italic toggle="yes">IKZF1</italic> intragenic deletions with RaScALL.</title>
          <p>Samples were analysed by RaScALL for the presence of target sequences representing <italic toggle="yes">IKZF1</italic> Δ2–3, Δ2–7 and Δ4–7 deletions. Deletion events reported by RaScALL were then compared to <italic toggle="yes">IKZF1</italic> deletions reported by MLPA analysis using P335 and P202 kits. (A) Minimum coverage (k-mers) across target sequences (log<sub>10</sub> scale) for targets representing <italic toggle="yes">IKZF1</italic> Δ2–3 deletion, Δ2–7 deletion or Δ4–7 deletion. Points are coloured concordant (blue) when the same <italic toggle="yes">IKZF1</italic> deletion was identified by MLPA or discordant (pink) when MLPA reported no <italic toggle="yes">IKZF1</italic> deletion for the sample. (B) Sample frequency for <italic toggle="yes">IKZF1</italic> status reported as either no deletion, Δ2–3 deletion, Δ2–7 deletion or Δ4–7 <italic toggle="yes">IKZF1</italic> deletion (minimum k-mer coverage &gt; = 10). Bars are coloured according to whether the <italic toggle="yes">IKZF1</italic> deletion reported by RaScALL was supported (Concordant, dark blue), or not supported (discordant, pink) by MLPA analysis.</p>
        </caption>
        <graphic xlink:href="pgen.1010300.g003" position="float"/>
      </fig>
    </sec>
    <sec id="sec008">
      <title>Detection of missense mutations</title>
      <p>While gene fusions define the majority of ALL subtypes, loss of function sequence variants <italic toggle="yes">PAX5</italic> p.P80R and <italic toggle="yes">IKZF1</italic> p.N159Y have been reported as independent driving events in leukaemic development, representing distinct ALL subtypes [<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>,<xref rid="pgen.1010300.ref041" ref-type="bibr">41</xref>]. Furthermore, cooperating missense mutations are often necessary for leukaemic transformation or are associated with high-risk disease. For example, activating mutations of <italic toggle="yes">JAK2</italic> are frequently observed with rearrangements of <italic toggle="yes">CRLF2</italic> and associated with the high-risk Ph-like subtype [<xref rid="pgen.1010300.ref010" ref-type="bibr">10</xref>,<xref rid="pgen.1010300.ref017" ref-type="bibr">17</xref>], while <italic toggle="yes">TP53</italic> variants are common in hypodiploid ALL [<xref rid="pgen.1010300.ref042" ref-type="bibr">42</xref>,<xref rid="pgen.1010300.ref043" ref-type="bibr">43</xref>]. Given the prognostic significance of these variants, target sequences were generated for a small range of recurrently observed pathogenic SNVs (<xref rid="pgen.1010300.t002" ref-type="table">Table 2</xref>). Calls made by RaScALL within the study cohort were compared with SNVs reported by GATK HaplotypeCaller.</p>
      <table-wrap position="float" id="pgen.1010300.t002">
        <object-id pub-id-type="doi">10.1371/journal.pgen.1010300.t002</object-id>
        <label>Table 2</label>
        <caption>
          <title>Single nucleotide variants targeted by RaScALL.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pgen.1010300.t002" id="pgen.1010300.t002g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">Gene</th>
                <th align="center" rowspan="1" colspan="1">Amino acid substitution (p.)</th>
                <th align="center" rowspan="1" colspan="1">Detection rate</th>
                <th align="center" rowspan="1" colspan="1">Clinical relevance</th>
                <th align="center" rowspan="1" colspan="1">Reference</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">PAX5</italic>
                </td>
                <td align="center" rowspan="1" colspan="1">P80R</td>
                <td align="center" rowspan="1" colspan="1">6/6 (100%)</td>
                <td align="center" rowspan="1" colspan="1">Loss of function</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pgen.1010300.ref041" ref-type="bibr">41</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">IKZF1</italic>
                </td>
                <td align="center" rowspan="1" colspan="1">N159Y</td>
                <td align="center" rowspan="1" colspan="1">4/4 (100%)</td>
                <td align="center" rowspan="1" colspan="1">Perturbed <italic toggle="yes">IKZF1</italic> function</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">ABL1</italic>
                </td>
                <td align="center" rowspan="1" colspan="1">T315I</td>
                <td align="center" rowspan="1" colspan="1">0/1 (0%)</td>
                <td align="center" rowspan="1" colspan="1">Resistance to tyrosine kinase inhibitors</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pgen.1010300.ref009" ref-type="bibr">9</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">CRLF2</italic>
                </td>
                <td align="center" rowspan="1" colspan="1">F232C</td>
                <td align="center" rowspan="1" colspan="1">8/8 (100%)</td>
                <td align="center" rowspan="1" colspan="1">Gain of function mutation</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pgen.1010300.ref044" ref-type="bibr">44</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="4" colspan="1">
                  <italic toggle="yes">JAK2</italic>
                </td>
                <td align="center" rowspan="1" colspan="1">I682F</td>
                <td align="center" rowspan="1" colspan="1">0/1 (0%)</td>
                <td align="center" rowspan="1" colspan="1">Gain of function mutation</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pgen.1010300.ref045" ref-type="bibr">45</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">R683G, R683S, R683T</td>
                <td align="center" rowspan="1" colspan="1">4/8 (50%)</td>
                <td align="center" rowspan="1" colspan="1">Gain of function mutation</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pgen.1010300.ref045" ref-type="bibr">45</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">T875N</td>
                <td align="center" rowspan="1" colspan="1">2/2 (100%)</td>
                <td align="center" rowspan="1" colspan="1">Gain of function mutation</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pgen.1010300.ref046" ref-type="bibr">46</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">R938Q</td>
                <td align="center" rowspan="1" colspan="1">1/1 (100%)</td>
                <td align="center" rowspan="1" colspan="1">Resistance to <italic toggle="yes">JAK2</italic> inhibitors</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pgen.1010300.ref047" ref-type="bibr">47</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="3" colspan="1">
                  <italic toggle="yes">NRAS</italic>
                </td>
                <td align="center" rowspan="1" colspan="1">G12A, G12C, G12D, G12S, G12V</td>
                <td align="center" rowspan="1" colspan="1">11/13 (85%)</td>
                <td align="center" rowspan="3" colspan="1">Associated with inferior outcome and increased risk of relapse</td>
                <td align="center" rowspan="3" colspan="1">[<xref rid="pgen.1010300.ref016" ref-type="bibr">16</xref>,<xref rid="pgen.1010300.ref048" ref-type="bibr">48</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">G13D</td>
                <td align="center" rowspan="1" colspan="1">2/4 (50%)</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Q61H, Q61K, Q61P</td>
                <td align="center" rowspan="1" colspan="1">4/4 (100%)</td>
              </tr>
              <tr>
                <td align="center" rowspan="3" colspan="1">
                  <italic toggle="yes">KRAS</italic>
                </td>
                <td align="center" rowspan="1" colspan="1">G12C, G12D, G12S, G12V</td>
                <td align="center" rowspan="1" colspan="1">11/12 (92%)</td>
                <td align="center" rowspan="3" colspan="1">Associated with inferior outcome and increased risk of relapse</td>
                <td align="center" rowspan="3" colspan="1">[<xref rid="pgen.1010300.ref016" ref-type="bibr">16</xref>,<xref rid="pgen.1010300.ref048" ref-type="bibr">48</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">G13D</td>
                <td align="center" rowspan="1" colspan="1">3/3 (100%)</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">A146P, A146V</td>
                <td align="center" rowspan="1" colspan="1">0/2 (0%)</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">TP53</italic>
                </td>
                <td align="center" rowspan="1" colspan="1">R209Q/R248Q, R209W/R248W</td>
                <td align="center" rowspan="1" colspan="1">3/3 (100%)</td>
                <td align="center" rowspan="1" colspan="1">Associated with poor prognosis</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pgen.1010300.ref043" ref-type="bibr">43</xref>,<xref rid="pgen.1010300.ref049" ref-type="bibr">49</xref>]</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
      <p>Pathogenic SNVs were detected in 59 of 72 cases (82%), including all instances of subtype defining variants <italic toggle="yes">PAX5</italic> p.P80R (n = 6) and <italic toggle="yes">IKZF1</italic> p.N159Y (n = 4). RaScALL detected <italic toggle="yes">JAK2</italic>, <italic toggle="yes">NRAS</italic> and <italic toggle="yes">KRAS</italic> variants at a lower frequency than was reported by GATK (<xref rid="pgen.1010300.t002" ref-type="table">Table 2</xref> and <xref rid="pgen.1010300.g001" ref-type="fig">Fig 1</xref>). Failure to identify variants in these three genes was attributed to low read coverage or low variant allele frequencies, resulting in fewer than 5 k-mers supporting the variant across each position of the target sequence. A variant occurring in <italic toggle="yes">ABL1</italic> went undetected by RaScALL despite high coverage across the genomic region. Inspection of the BAM file revealed an additional SNV on the same allele upstream of the targeted amino acid position. An in-exact match to the final k-mer of the provided target sequence resulted in false-negative detection of these two pathogenic variants (<xref rid="pgen.1010300.g002" ref-type="fig">Fig 2B</xref>).</p>
    </sec>
    <sec id="sec009">
      <title>RaScALL accurately identifies subtype defining alterations in a validation cohort</title>
      <p>Previously described gene fusions and SNVs represent only a portion of clinically relevant genomic alterations affecting ALL patients, limiting the applicability of RaScALL. To enable detection of a broader range of genomic alterations, we performed a literature search identifying an additional 46 gene fusions and 26 SNVs reported in multiple ALL patients and associated with functional effects [<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>,<xref rid="pgen.1010300.ref008" ref-type="bibr">8</xref>,<xref rid="pgen.1010300.ref050" ref-type="bibr">50</xref>–<xref rid="pgen.1010300.ref067" ref-type="bibr">67</xref>]. Targets for these variants, and any alterations undetected in the study cohort, were generated using RaScALL’s custom target generation tool (see <xref rid="sec012" ref-type="sec">Materials and Methods</xref>), resulting in an expanded target set representing 75 distinct gene fusions and sequence variants affecting 14 cancer-related genes (<xref rid="pgen.1010300.s005" ref-type="supplementary-material">S5 Table</xref>). Run time for creation of the additional 1108 target sequences by the custom target generation tool was less than 3 minutes. Targets representing intragenic deletions of <italic toggle="yes">ERG</italic> and <italic toggle="yes">PAX5</italic> were also manually generated. To assess applicability against a greater number of B-ALL subgroups than was represented by the study cohort, a random selection of 100 B-ALL patient samples from a published study by Gu <italic toggle="yes">et al</italic>. 2019 [<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>] were analysed by RaScALL using this updated target set (target set B). This validation cohort contained samples representing B-ALL subgroups absent from the study cohort including <italic toggle="yes">MEF2D</italic>r and <italic toggle="yes">PAX5</italic>alt (<xref rid="pgen.1010300.s006" ref-type="supplementary-material">S6 Table</xref>). The effectiveness of RaScALL to identify subtype defining genomic alterations and clinically relevant cooperating variants was determined by comparing the genomic alteration identified by RaScALL with those reported by Gu <italic toggle="yes">et al</italic>. 2019 [<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>] in the original publication for these selected samples.</p>
      <p>RaScALL reported concordant gene fusions in 63 of 66 patient samples (<xref rid="pgen.1010300.g004" ref-type="fig">Fig 4A</xref>) and identified the reciprocal gene fusion in 21 samples (<xref rid="pgen.1010300.s005" ref-type="supplementary-material">S5 Table</xref>). No fusion was reported for the 29 samples lacking a clinically relevant gene fusion. Discordant results, based on alterations reported in Gu <italic toggle="yes">et al</italic>. 2019 [<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>], were observed in 7 patient samples, where RaScALL either failed to detect the reported fusion (n = 3) or falsely predicted a gene fusion (n = 4). Undetected fusions included one instance of <italic toggle="yes">IGH-CRLF2</italic>, one sample with <italic toggle="yes">BCR-ABL1</italic> with limited read coverage over the fusion breakpoint, and one sample with <italic toggle="yes">KMT2A-AFF1</italic> with a breakpoint not represented in the target set, although the reciprocal fusion (<italic toggle="yes">AFF1-KMT2A</italic>) was identified by RaScALL. False-positive gene fusions including <italic toggle="yes">P2RY8-CRLF2</italic> (n = 3) and <italic toggle="yes">DDX3X-MLLT10</italic> (n = 1) were detected with minimal coverage over the target sequence (minimum k-mer coverage &lt; 5).</p>
      <fig position="float" id="pgen.1010300.g004">
        <object-id pub-id-type="doi">10.1371/journal.pgen.1010300.g004</object-id>
        <label>Fig 4</label>
        <caption>
          <title>RaScALL accurately detects subtype defining genetic variants in a validation cohort of 100 B-ALL patient samples.</title>
          <p>Fusions (A) and variants (B) detected by RaScALL and their concordance with clinically reported alterations. The vertical axis indicates the number of detected alterations while the horizontal axis indicates the specific gene fusion (A) or gene in which the variant occurred (B). Concordant results are indicated in blue and discordant indicated in dark red for false negative results and light red for false positive results. (C) Runtimes for RaScALL in minutes. Wall clock time for 100 samples represented as boxplots. The vertical axis indicates the separate run times for indexing of raw data and assessment of variants with different target sets. The Number of targets in each set is indicated.</p>
        </caption>
        <graphic xlink:href="pgen.1010300.g004" position="float"/>
      </fig>
      <p>Missense mutations and insertions were correctly identified by RaScALL in 75% of cases (43 of 57 reported sequence variants detected) (<xref rid="pgen.1010300.g004" ref-type="fig">Fig 4B</xref>). As with the initial study cohort, missed variants were attributed to limited read coverage (low-level gene expression or low variant allele frequency). An <italic toggle="yes">IL7R</italic> p.T244I variant was correctly detected in 33 patient samples but determined to represent a benign polymorphism based upon the population allele frequency reported in the Genome Aggregation Database (gnomAD), while an <italic toggle="yes">IL7R</italic> p.S252ins predicted in 19 samples represented a false positive variant attributed to a homopolymer sequencing artefact. While not reported by Gu <italic toggle="yes">et al</italic>. 2019 [<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>], pathogenic <italic toggle="yes">CRLF2</italic> and <italic toggle="yes">TP53</italic> variants were correctly identified in 6 patient samples and confirmed by visual inspection with IGV. Focal deletions of <italic toggle="yes">IKZF1</italic>, <italic toggle="yes">PAX5</italic> and <italic toggle="yes">ERG</italic> were likewise identified in 31 cases.</p>
      <p>Subtype defining alterations were detected in 67 of 100 patients. In the remaining 33 samples, 23 did not have a reportable fusion or loss of function sequence variant, while 8 samples had rare gene fusions with no available target sequence. Causative lesions were undetected by RaScALL in only 2 cases (<xref rid="pgen.1010300.s005" ref-type="supplementary-material">S5 Table</xref>). Runtimes for this random cohort were longer than reported previously, due to increased read length (100bp PE), sequencing depth (median 106 million reads), and an increase in the number of target sequences. Increasing the number of non-<italic toggle="yes">IGH</italic> fusion targets from 39 to 1181 resulted in an average increase of 143 seconds for non-<italic toggle="yes">IGH</italic> gene fusion detection. Overall median runtime was 22.6 minutes, attributed primarily to the assessment of <italic toggle="yes">IGH</italic> gene fusions (<xref rid="pgen.1010300.g004" ref-type="fig">Fig 4C</xref>). Runtimes exceeding 50 minutes were reported for 3 samples with sequencing depth greater than 140 million PE reads, and all with <italic toggle="yes">IGH-DUX4</italic> fusions expected to result in high-level expression of the <italic toggle="yes">IGH</italic> locus.</p>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="sec010">
    <title>Discussion</title>
    <p>RNA-seq produces a comprehensive overview of patient disease, allowing clinicians to accurately assign risk and design personalised treatment plans of chemotherapy with or without targeted therapies. Consequently, several researchers have endorsed the use of this technology as a front-line diagnostic tool in future clinical trials [<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>–<xref rid="pgen.1010300.ref007" ref-type="bibr">7</xref>,<xref rid="pgen.1010300.ref068" ref-type="bibr">68</xref>]. However, successful integration of genomic data in a clinical setting requires bioinformatics tools that can rapidly and accurately identify clinically relevant variants [<xref rid="pgen.1010300.ref007" ref-type="bibr">7</xref>,<xref rid="pgen.1010300.ref022" ref-type="bibr">22</xref>]. Large cohort studies utilising RNA-seq have identified multiple recurrently observed and prognostically significant genomic alterations for which rapid targeted variant analysis can be performed, reducing the reliance on computationally intensive <italic toggle="yes">de novo</italic> variant detection methods that limit clinical translation speed. This study aimed to develop a bioinformatic tool utilising a target variant detection approach for rapid identification and reporting of clinically relevant genomic alterations in ALL.</p>
    <p>Gene fusions represent the most common driver mutations in patients with ALL, and many are associated with a specific risk profile [<xref rid="pgen.1010300.ref001" ref-type="bibr">1</xref>–<xref rid="pgen.1010300.ref003" ref-type="bibr">3</xref>]. Loss of function mutations of <italic toggle="yes">IKZF1</italic> and <italic toggle="yes">PAX5</italic> are less prevalent, affecting fewer than 1% of paediatric B-ALL patients, but becoming more common in adolescent and young adult (AYA) and adult cohorts with <italic toggle="yes">PAX5</italic> p.P80R detected in 3–4% of patients [<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>]. RaScALL enables accurate and simultaneous detection of both mutation types, in greater than 95% of patient samples that carry the mutation, within minutes. False-negative results were reported in a small proportion of cases due to either uncommon exon-exon breakpoints not represented in the target set, or the presence of a patient-specific polymorphism in the first or final k-mer of the target sequence. These limitations can be mitigated by relying on public population-scale genetic variation databases, such as 1000 genomes [<xref rid="pgen.1010300.ref069" ref-type="bibr">69</xref>] or gnomAD [<xref rid="pgen.1010300.ref070" ref-type="bibr">70</xref>], that have identified rare and common variants across a diverse set of global populations. Careful curation of available variant data is recommended when generating potential target sequences.</p>
    <p>Gene fusions involving the cytokine receptors <italic toggle="yes">CRLF2</italic> and <italic toggle="yes">EPOR</italic> with <italic toggle="yes">IGH/IGK</italic> occur in approximately 6–14% of B-ALL diagnoses for older children, adolescents and adults and are associated with high-risk disease [<xref rid="pgen.1010300.ref022" ref-type="bibr">22</xref>]. However, few of the currently available fusion calling algorithms can reliably detect these alterations due to difficulty mapping to IG loci [<xref rid="pgen.1010300.ref023" ref-type="bibr">23</xref>,<xref rid="pgen.1010300.ref025" ref-type="bibr">25</xref>]. In this study, we successfully identified <italic toggle="yes">IGH-CRLF2</italic> and <italic toggle="yes">IGH-EPOR</italic> alterations in 95 and 83% of tested cases respectively, demonstrating similar sensitivity to FusionCatcher [<xref rid="pgen.1010300.ref030" ref-type="bibr">30</xref>], one of the few fusion calling algorithms capable of detecting <italic toggle="yes">IGH</italic> gene fusions.</p>
    <p><italic toggle="yes">DUX4r</italic> are also frequently missed by alignment-based fusion calling algorithms [<xref rid="pgen.1010300.ref023" ref-type="bibr">23</xref>] in addition to being cryptic to standard cytogenetic analysis and fluorescent <italic toggle="yes">in situ</italic> hybridisation [<xref rid="pgen.1010300.ref071" ref-type="bibr">71</xref>]. <italic toggle="yes">DUX4</italic> expression is a reliable indicator of <italic toggle="yes">DUX4</italic>r [<xref rid="pgen.1010300.ref013" ref-type="bibr">13</xref>,<xref rid="pgen.1010300.ref072" ref-type="bibr">72</xref>], however, the presence of additional <italic toggle="yes">DUX4</italic> pseudo-gene copies in the reference genome, showing an almost identical DNA sequence to the annotated <italic toggle="yes">DUX4</italic> gene, complicates the accurate determination of <italic toggle="yes">DUX4</italic> expression by alignment [<xref rid="pgen.1010300.ref023" ref-type="bibr">23</xref>,<xref rid="pgen.1010300.ref072" ref-type="bibr">72</xref>]. Direct detection of <italic toggle="yes">DUX4</italic> expression across the first 700b of the <italic toggle="yes">DUX4</italic> transcript using RaScALL correlated directly with samples identified as <italic toggle="yes">DUX4</italic>r by gene expression profiling, enabling more sensitive detection of <italic toggle="yes">DUX4</italic>r than alignment-based tools. Given that patients with this ALL subtype typically demonstrate an excellent prognosis, early detection of patients with this lesion can assist in clinical decisions regarding treatment intensity [<xref rid="pgen.1010300.ref073" ref-type="bibr">73</xref>].</p>
    <p>In addition to reporting subtype defining genomic alterations, RaScALL can detect cooperating missense mutations and focal gene deletions, ensuring rapid reporting of multiple clinically relevant genomic alterations required for appropriate prognostication of patient disease. However, detection of focal gene deletions is limited to intragenic deletions resulting in aberrant transcript isoforms. Whole gene deletions and deletions of exon 1 resulting in loss of allelic transcription cannot be identified from RNA-seq data. For these reasons, DNA-based assays for copy number variant analysis are still recommended where patient material is available. Furthermore, detection of missense variants via pseudo-alignment is sensitive to sequencing coverage, with lowly expressed variants including <italic toggle="yes">JAK2</italic> being missed in a proportion of cases and analysis being limited to a small number of targeted variants. RaScALL requires a minimum of 5 reads spanning the target region to contain the altered allele for reliable detection of sequence variants (i.e., 25X coverage across region of interest for subclonal variants in 20% of sample). Follow-up analysis utilising more sensitive alignment-based <italic toggle="yes">de novo</italic> small variant detection tools (e.g., GATK HaplotypeCaller) is therefore recommended for the identification of less common or lowly expressed sequence variants.</p>
    <p>A key advantage of RaScALL is the speed with which it can identify clinically relevant genomic alterations for patient prognostication. Most <italic toggle="yes">de novo</italic> variant detection tools depend upon the alignment of reads, a time and memory-consuming process. Consistent with previous benchmarking studies [<xref rid="pgen.1010300.ref023" ref-type="bibr">23</xref>,<xref rid="pgen.1010300.ref027" ref-type="bibr">27</xref>] we confirmed mean run times 0.5 hours for the memory intensive fusion calling algorithm <italic toggle="yes">arriba</italic> increasing to 15 hours for the low-memory tool <italic toggle="yes">SOAPfuse</italic>. Sequence variant detection by GATK similarly requires several hours for completion of all steps in the GATK best practices pipeline [<xref rid="pgen.1010300.ref074" ref-type="bibr">74</xref>]. In contrast, RaScALL can identify gene fusions and sequence variants of interest in under 30 minutes, with a moderate memory allocation (5-20GB depending on length and depth of sequencing). When implemented within a clinical sequencing laboratory using a hypbrid or commercial cloud computing environment, higher speed and lower memory utilisation translates to lower overall computing costs for bioinformatic analysis [<xref rid="pgen.1010300.ref035" ref-type="bibr">35</xref>].</p>
    <p><italic toggle="yes">De novo</italic> variant detection tools can generate false-positive predictions due to sequencing artefacts and alignment issues [<xref rid="pgen.1010300.ref023" ref-type="bibr">23</xref>,<xref rid="pgen.1010300.ref027" ref-type="bibr">27</xref>,<xref rid="pgen.1010300.ref075" ref-type="bibr">75</xref>]. In the case of gene fusions, read-through transcripts and <italic toggle="yes">cis-</italic>splicing can also result in a low number of chimeric transcripts without underlying chromosomal alterations [<xref rid="pgen.1010300.ref076" ref-type="bibr">76</xref>]. In our study, this was observed in the validation cohort with the <italic toggle="yes">P2RY8-CRLF2</italic> gene fusion, highlighting the need for caution regarding fusion sequences detected by RaScALL with very low coverage. Likewise, target sequences containing homopolymer stretches can result in false-positive detection of InDels due to sequencing error (e.g. <italic toggle="yes">ILR7</italic> p.S252ins). Importantly, by limiting the search space to known alterations and requiring an exact match to the expected breakpoint sequence we greatly reduce the false positive rate compared to alignment-based variant detection tools. This eliminates the need for consensus between multiple variant detection tools [<xref rid="pgen.1010300.ref023" ref-type="bibr">23</xref>,<xref rid="pgen.1010300.ref027" ref-type="bibr">27</xref>] or extensive filtering and manual data curation [<xref rid="pgen.1010300.ref025" ref-type="bibr">25</xref>], which limit the speed of clinical translation.</p>
    <p>Targeted variant detection approaches cannot detect the presence of novel disease-causing variants or identify the full range of variants that may potentially contribute to leukaemic progression. Subtype defining lesions, currently detectable with RaScALL represent 50–70% of paediatric and 60–85% of adult B-ALL samples [<xref rid="pgen.1010300.ref002" ref-type="bibr">2</xref>,<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>,<xref rid="pgen.1010300.ref077" ref-type="bibr">77</xref>]. Fewer target sequences are available for detection of subtype defining alterations in T-cell ALL (T-ALL) which represent 15–25% of ALL cases [<xref rid="pgen.1010300.ref078" ref-type="bibr">78</xref>]. This is in part due to the greater variability in sequence variants observed [<xref rid="pgen.1010300.ref079" ref-type="bibr">79</xref>], the reduced availability of T-ALL samples for RNA-seq analysis and a greater ambiguity around the prognostic significance of T-ALL associated lesions [<xref rid="pgen.1010300.ref078" ref-type="bibr">78</xref>]. Given the highly heterogeneous nature of ALL, new genomic alterations of clinical relevance will continue to be identified [<xref rid="pgen.1010300.ref007" ref-type="bibr">7</xref>,<xref rid="pgen.1010300.ref022" ref-type="bibr">22</xref>,<xref rid="pgen.1010300.ref079" ref-type="bibr">79</xref>], while ongoing research will continue to refine the associated prognostic impact of these lesions. As such the repertoire of ALL specific alterations for detection from RNA-seq will grow and change over time. To accommodate this, we have provided command line scripts for generating additional target sequences representing canonical gene fusions, SNVs and InDels to allow for rapid expansion of variants for analysis with RaScALL.</p>
  </sec>
  <sec sec-type="conclusions" id="sec011">
    <title>Conclusion</title>
    <p>RNA-seq is being increasingly utilised in clinical trials for ALL as it enables more refined subclassification of patient samples than standard diagnostic tests. Effective implementation of this technology is however dependent on bioinformatic analysis that allows for accurate and reliable detection of clinically relevant genomic alterations in a clinically relevant time frame. In this setting, where the presence or absence of a finite list of known genomic alterations is needed to determine patient risk, a targeted variant detection approach can be highly beneficial. RaScALL provides comparable detection of clinically relevant ALL gene fusions and co-occurring mutations and superior detection of <italic toggle="yes">DUX4</italic>r than alignment-based <italic toggle="yes">de novo</italic> variant calling tools, without the need for extensive filtering and manual curation of detected alterations. Runtimes are significantly shorter than most alignment-based tools available for <italic toggle="yes">de novo</italic> gene fusion and sequence variant detection, and the lower memory requirements mean that analysis can be easily scaled across large computational resources. Using the custom target generation tool additional target sequences can be easily generated, allowing users to expand or adapt their analysis to suit reporting guidelines. RaScALL provides a fast, light-weight tool to quickly screen RNA-seq data for clinically relevant alterations, enabling rapid reporting of patient-specific ALL variants to assist with prognostication and treatment allocation.</p>
  </sec>
  <sec sec-type="materials|methods" id="sec012">
    <title>Materials and methods</title>
    <sec id="sec013">
      <title>Ethics statement</title>
      <p>Ethical approval for sample collection and analysis was granted by the following Human Research Ethics Committees (HRECs) within South Australia; the Central Adelaide Local Health Network (CALHN) Human Research Ethics Committee and the Women’s and Children’s Health Network (WCHN) Human Research Ethics Committee. Approval for the collection of samples outside of South Australia was granted under the National Mutual Acceptance Scheme. Informed written consent was obtained from patients, or in the case of children, their legal parent/guardian.</p>
    </sec>
    <sec id="sec014">
      <title>RaScALL overview</title>
      <p>A k-mer count table (k = 31) is generated from patient RNA-seq data using <italic toggle="yes">jellyfish</italic> v2.2.6 [<xref rid="pgen.1010300.ref033" ref-type="bibr">33</xref>]. Variant detection is then performed with <italic toggle="yes">km</italic> [<xref rid="pgen.1010300.ref028" ref-type="bibr">28</xref>] using the <italic toggle="yes">jellyfish</italic> count table and target sequences as input. Targets are separated according to the type of variant for assessment (Fusion, IGH Fusion, DUX4, SNV, and focal deletion) and <italic toggle="yes">km</italic> find_mutation is performed separately for each variant type, with the output written to a text file. A custom R script then filters and annotates variants generating a single output file containing detected clinically relevant alterations. RaScALL was run on a 32 thread 128 GB RAM HPC node at the South Australian Health and Medical Research Institute (SAHMRI). Code and additional scripts for running RaScALL are available from the GitHub repository (<ext-link xlink:href="https://github.com/jimmybgammyknee/RaScALL" ext-link-type="uri">https://github.com/j-rehn/RaScALL</ext-link>).</p>
    </sec>
    <sec id="sec015">
      <title>Generation of target sequences for variant detection within the study cohort</title>
      <p>Target sequences applied to the study cohort (target set A) were designed as previously described [<xref rid="pgen.1010300.ref028" ref-type="bibr">28</xref>] for gene fusions involving exon-exon breakpoints and single nucleotide variants, limiting this list to recurrently observed genomic alteration noted in the literature as being clinically relevant. Briefly, for gene fusions, the break-point genomic coordinates reported by FusionCatcher [<xref rid="pgen.1010300.ref030" ref-type="bibr">30</xref>] for previously analysed patient samples were used to extract nucleotide sequences from UCSC with the getDNA portal and incorporated 31b of sequence from each gene involved in the fusion. Targets for sequence variants were also generated using the UCSC getDNA portal, ensuring that the reference sequence was in-frame with 33b on either side of the amino acid position(s) of interest. To detect transcripts indicative of <italic toggle="yes">IKZF1</italic> deletions, target sequences containing 31b of each exon on either side of the potential deletion breakpoint were created.</p>
      <p>Targets for detection of <italic toggle="yes">DUX4</italic> expression were generated using the first 700b of the NCBI Reference Sequences transcripts of DUX4 (NM_001306068.3) and the hg38 alternate locus containing DUX4 homolog (NT_187650.1). A total of twelve non-overlapping target sequences of 70b length each were generated, excluding regions between 141-210b of the mRNA transcript which was highly homologous to multiple genomic locations within the human reference genome. Targets representing potential breakpoints for <italic toggle="yes">IGH-CRLF2</italic> and <italic toggle="yes">EPOR-IGH</italic> rearrangements were generated by combining 50bp sequence 5’ of reported <italic toggle="yes">CRLF2</italic> and <italic toggle="yes">EPOR</italic> breakpoints with sequences from all <italic toggle="yes">IGHJ</italic>, <italic toggle="yes">IGHD</italic> and <italic toggle="yes">IGK</italic> alleles downloaded from IMGT, the international ImMunoGeneTics information system (<ext-link xlink:href="http://www.imgt.org/" ext-link-type="uri">http://www.imgt.org</ext-link>).</p>
    </sec>
    <sec id="sec016">
      <title>Generation of target sequences for variant detection within the validation cohort</title>
      <p>Target sequences applied to the validation cohort (target set B) were generated by combining target set A with additional target sequences produced with RaScALL’s custom target generation tools (<ext-link xlink:href="https://github.com/jimmybgammyknee/RaScALL" ext-link-type="uri">https://github.com/j-rehn/RaScALL</ext-link>). Briefly, tab-separated files were compiled containing gene names, RefSeq transcript identifiers and either breakpoint exon numbers (gene fusions) or amino acid position (SNV/InDels) for the additional gene fusions/ sequence variants of interest. These were supplied to the custom_targets.sh script along with the UCSC hg19 human reference genome and associated gtf file, which identifies the genomic locations required for the target sequence and prints this to a separate FASTA file for each fusion/variant. ALL specific gene fusions, single nucleotide variants and focal gene deletions for clinical reporting were identified from the literature, limited to variants that were multiply reported. To reduce the likelihood of false-negatives target regions involved in gene fusions with exon-exon breakpoints were searched in gnomAD [<xref rid="pgen.1010300.ref070" ref-type="bibr">70</xref>] to identify single nucleotide polymorphisms (SNP) with a variant allele frequency greater than 0.01. When identified an additional target sequence containing the SNP was manually generated.</p>
    </sec>
    <sec id="sec017">
      <title>Patient samples in the study cohort</title>
      <p>The study cohort consisted of RNA-seq data from 180 Australian ALL patient samples taken either at diagnosis (n = 149) or relapse (n = 31) selected from a larger pool of patient samples referred to the South Australian Health and Medical Research Institute (SAHMRI) for genomic testing (Adelaide, Australia). The cohort included 160 B-ALL, 18 T-ALL and 2 samples with acute bi-phenotypic leukaemia or acute undifferentiated leukaemia, each with an identified driver mutation or associated aneuploidy representing commonly observed clinically relevant genomic alterations. Library preparation for mRNA sequencing was performed using either Truseq Stranded mRNA LT Kit (Illumina, CA, USA) or Universal Plus mRNA-Seq with NuQuant (Tecan, CA, USA) from 400ng of total RNA as per the manufacturer’s instructions. Samples were sequenced by either Illumina HiSeq 2000 or NextSeq 500 platforms producing 75b length paired-end (PE) reads with a median read depth of 70M reads.</p>
      <p>Fluorescent in situ hybridization (FISH) was performed on a subset of patient samples showing surface expression of CRLF2 by flow-cytometry. <italic toggle="yes">IGH-CRLF2</italic> rearrangements were detected using two separate break-apart probes, a <italic toggle="yes">CRLF2</italic> dual colour probe (Cytocell) and a Vysis IGH dual colour probe (Abbott). Where material was available <italic toggle="yes">IKZF1</italic> deletions were detected by multiplex ligation-dependent probe amplification using two SALSA Reference kits (P335 and P202, MRC-Holland, Amsterdam, Netherlands) according to the manufacturer’s instructions and data was analysed using Coffalyser software.</p>
    </sec>
    <sec id="sec018">
      <title><italic toggle="yes">De novo</italic> variant detection performed for the study cohort</title>
      <p>RNA-seq data was analysed through an in-house bioinformatics pipeline for the detection of gene fusions and single nucleotide variants (SNV). For SNV detection, raw FASTQ data was aligned to the human reference genome (GRCh37) with STAR aligner (v 2.5.3) [<xref rid="pgen.1010300.ref080" ref-type="bibr">80</xref>] using 2-pass mode. Variant calling was performed by <italic toggle="yes">GATK HaplotypeCaller</italic> [<xref rid="pgen.1010300.ref029" ref-type="bibr">29</xref>] and annotated with <italic toggle="yes">Annovar</italic> [<xref rid="pgen.1010300.ref081" ref-type="bibr">81</xref>]. Only variants with a minimum of 10 reads over the variant position and a VAF &gt; 0.1 were reported and detected variants with an allele frequency &lt; 0.2 were visualised in IGV [<xref rid="pgen.1010300.ref082" ref-type="bibr">82</xref>] to confirm they represented true variants and not sequencing artefacts.</p>
      <p>Gene fusions were detected utilising <italic toggle="yes">SOAPfuse</italic> v1.26 [<xref rid="pgen.1010300.ref031" ref-type="bibr">31</xref>], <italic toggle="yes">JAFFA</italic> v1.09 [<xref rid="pgen.1010300.ref032" ref-type="bibr">32</xref>], <italic toggle="yes">fusionCatcher</italic> (fusioncatcher.py 0.99.7c beta) [<xref rid="pgen.1010300.ref030" ref-type="bibr">30</xref>] and <italic toggle="yes">arriba</italic> v2.1.0 [<xref rid="pgen.1010300.ref023" ref-type="bibr">23</xref>]. To reduce false positives only fusions detected by multiple callers were considered as likely candidates except for fusions involving <italic toggle="yes">IGH</italic> which are frequently only detected by <italic toggle="yes">fusionCatcher</italic> or to a lesser extent <italic toggle="yes">arriba</italic>. For <italic toggle="yes">IGH-CRLF2</italic> fusions all samples in the study cohort had FISH supporting the presence of the rearrangement, while <italic toggle="yes">IGH-EPOR</italic> rearrangements were confirmed by visual inspection of the BAM file. Gene expression profiling was performed to confirm the presence of rearrangements involving <italic toggle="yes">DUX4</italic>. Gene counts were generated from the STAR aligned samples using featureCounts [<xref rid="pgen.1010300.ref083" ref-type="bibr">83</xref>] and TMM normalised with edgeR [<xref rid="pgen.1010300.ref084" ref-type="bibr">84</xref>]. Hierarchical clustering was then performed using previously published gene lists [<xref rid="pgen.1010300.ref072" ref-type="bibr">72</xref>,<xref rid="pgen.1010300.ref085" ref-type="bibr">85</xref>,<xref rid="pgen.1010300.ref086" ref-type="bibr">86</xref>].</p>
    </sec>
    <sec id="sec019">
      <title>Application of RaScALL to the validation cohort</title>
      <p>To assess the clinical applicability of RaScALL in a diagnostic setting a validation cohort of 100 samples was selected from publicly available data provided by Gu <italic toggle="yes">et al</italic>. 2019 [<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>] (European Genome-phenome Archive: EGAD00001004461 and EGAD00001004463). Samples were selected at random after excluding those reported as hyperdiploid or hypodiploid. BAM files were converted to FASTQ using <italic toggle="yes">samtools</italic> (v1.3.1) and the resultant FASTQ files were analysed by RaScALL. Gene fusions, SNVs and InDels reported as part of the Gu <italic toggle="yes">et al</italic>. 2019 [<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>] study for these samples were utilised to evaluate the accuracy of RaScALL for the detection of clinically relevant variants. Methods describing de novo variant detection of genomic alterations for these samples can be found in the original publication (Gu <italic toggle="yes">et al</italic>. 2019 [<xref rid="pgen.1010300.ref005" ref-type="bibr">5</xref>]). SNVs detected by RaScALL but not reported as part of the study were visualised in IGV. Runtimes reported include indexing of FASTQ files with <italic toggle="yes">jellyfish</italic> (12 threads) and variant detection by <italic toggle="yes">km</italic>.</p>
    </sec>
    <sec id="sec020">
      <title>Memory and run time evaluation</title>
      <p>Maximum memory usage for <italic toggle="yes">jellyfish</italic> and <italic toggle="yes">km</italic> was estimated as previously described [<xref rid="pgen.1010300.ref034" ref-type="bibr">34</xref>]. For indexing of raw RNA-seq data with <italic toggle="yes">jellyfish</italic>, tests were performed on simulated fastq files generated with randomreads.sh (<ext-link xlink:href="http://sourceforge.net/projects/bbmap/" ext-link-type="uri">sourceforge.net/projects/bbmap/</ext-link>) from the Human Ensembl GRCh38 reference transcriptome. Memory requirements for variant detection with <italic toggle="yes">km</italic> were assessed utilising the 180 samples from the study cohort with PE read length 75b and mean read depth 70M. Runtime for <italic toggle="yes">jellyfish</italic> was measured using the bash internal variable SECONDS and averaged over three runs. Elapsed time reported by <italic toggle="yes">km</italic> for a given set of targets was extracted from the raw output files.</p>
      <p>An additional evaluation of runtime and memory was also performed between RaScALL and the fusion calling algorithms employed for de novo fusion detection in the study cohort (<italic toggle="yes">FusionCatcher</italic>, <italic toggle="yes">SOAPfuse</italic>, <italic toggle="yes">JAFFA</italic> and <italic toggle="yes">arriba</italic>). For this analysis 9 samples from the study cohort, representing high (80+ million), moderate (50–80 million) and low (&lt; 50 million) read depths, were selected for benchmarking (A2638-12600, ADI-0158, AYAI-0004-REL1, AYAII-0063, CH-A1725, CH-A2497, CH-A5243-DIA, CHI-0452-DIA1-BM, CHI-0511-DIA1-PB). Each sample was processed individually by each program on a HPC node with 16CPU and 128GB RAM. The resource allocation for individual jobs was a maximum of 8CPU and 12 threads. Elapsed time and maximum resident set size (Max RSS) for individual jobs was extracted from the slurm workload manager at completion of analysis.</p>
    </sec>
  </sec>
  <sec id="sec021" sec-type="supplementary-material">
    <title>Supporting information</title>
    <supplementary-material id="pgen.1010300.s001" position="float" content-type="local-data">
      <label>S1 Table</label>
      <caption>
        <title>Clinical information and reported genetic alterations for patients in the study cohort.</title>
        <p>(XLSX)</p>
      </caption>
      <media xlink:href="pgen.1010300.s001.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pgen.1010300.s002" position="float" content-type="local-data">
      <label>S2 Table</label>
      <caption>
        <title>Summary of target sequences utilised by RaScALL for variant detection within the study cohort (target set A).</title>
        <p>(XLSX)</p>
      </caption>
      <media xlink:href="pgen.1010300.s002.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pgen.1010300.s003" position="float" content-type="local-data">
      <label>S3 Table</label>
      <caption>
        <title>Run time and peak memory usage for generating k-mer count table with <italic toggle="yes">jellyfish</italic> using simulated RNA-seq data.</title>
        <p>(XLSX)</p>
      </caption>
      <media xlink:href="pgen.1010300.s003.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pgen.1010300.s004" position="float" content-type="local-data">
      <label>S4 Table</label>
      <caption>
        <title>Genomic alterations detected by RaScALL for the study cohort and a comparison against detection of these alterations by alignment-based <italic toggle="yes">de novo</italic> detection tools or MLPA.</title>
        <p>(XLSX)</p>
      </caption>
      <media xlink:href="pgen.1010300.s004.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pgen.1010300.s005" position="float" content-type="local-data">
      <label>S5 Table</label>
      <caption>
        <title>Summary of target sequences utilised by RaScALL for variant detection within the validation cohort (target set B).</title>
        <p>(XLSX)</p>
      </caption>
      <media xlink:href="pgen.1010300.s005.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pgen.1010300.s006" position="float" content-type="local-data">
      <label>S6 Table</label>
      <caption>
        <title>Clinical information and genomic alterations detected by RaScALL for the validation cohort.</title>
        <p>(XLSX)</p>
      </caption>
      <media xlink:href="pgen.1010300.s006.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pgen.1010300.s007" position="float" content-type="local-data">
      <label>S1 Fig</label>
      <caption>
        <title>Hierarchical clustering of B-ALL patients in study cohort utilising differentially expressed genes reported for patients with <italic toggle="yes">DUX4</italic>-rearrangement (<italic toggle="yes">DUX4</italic>r).</title>
        <p>Hierarchical clustering of CPM normalised expression data using published gene sets by (A) Yeoh et al., 2002 (85) (B) Harvey et al., 2010 (86) and (C) Zhang et al., 2016 (72). Each column represents a single B-ALL patient. Driver gene fusion identified for the sample is indicated at the top of each heatmap and coloured according to the key (<italic toggle="yes">IGH-DUX4</italic> fusion coloured red). Patients identified as <italic toggle="yes">DUX4</italic>r in the cohort are indicated with dark blue.</p>
        <p>(TIF)</p>
      </caption>
      <media xlink:href="pgen.1010300.s007.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pgen.1010300.s008" position="float" content-type="local-data">
      <label>S2 Fig</label>
      <caption>
        <title>Comparison of overall runtime and maximum memory usage between RaScALL and four alignment-based fusion calling algorithms (<italic toggle="yes">FusionCatcher</italic>, <italic toggle="yes">Arriba</italic>, <italic toggle="yes">JAFFA</italic>, and <italic toggle="yes">SOAPfuse</italic>).</title>
        <p>Elapsed time and maximum resident set size (Max RSS) were obtained for 9 patient samples from the study cohort representing high (80+ million), moderate (50–80 million) and low (&lt; 50 million) read depths. Analysis was performed on a HPC Node with 16CPU and 128GB RAM. Resources allocated for each job was a maximum of 8CPU and 12 threads. Elapsed time and Max RSS were obtained from the slurm workload manager at the completion of individual jobs. Boxplot representing (A) elapsed time (minutes) and (B) Max RSS (GB) for each program. Points represent individual samples coloured according to read depth as indicated in the key above.</p>
        <p>(TIF)</p>
      </caption>
      <media xlink:href="pgen.1010300.s008.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pgen.1010300.s009" position="float" content-type="local-data">
      <label>S3 Fig</label>
      <caption>
        <title>DUX4 target sequences detected in samples from the study cohort.</title>
        <p>Number of DUX4 targets detected in samples within the study cohort (A) and the minimum k-mer coverage across DUX4 target sequences (B) for each sample and reported on a log<sub>10</sub> scale. Samples from patients reported as <italic toggle="yes">DUX4</italic>r based on hierarchical cluster analysis are shown in red and non-<italic toggle="yes">DUX4</italic>r patients indicated in blue.</p>
        <p>(TIF)</p>
      </caption>
      <media xlink:href="pgen.1010300.s009.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pgen.1010300.s010" position="float" content-type="local-data">
      <label>S4 Fig</label>
      <caption>
        <title>Upset plot comparing detection rate of 164 clinically relevant gene fusions utilising both individual programs and combinations of RaScALL, <italic toggle="yes">FusionCatcher</italic>, <italic toggle="yes">arriba</italic>, <italic toggle="yes">JAFFA</italic> and <italic toggle="yes">SOAPfuse</italic>.</title>
        <p>(A) Intersection of reported driver gene fusions represented as a percentage of total driver gene fusions present in the cohort (n = 164). Each column corresponds to fusion calling algorithm (final 5 columns) or sets of fusion callers (dots connected by lines below the X axis). Only fusions reported by all fusion callers included in the set are considered. The percentage of driver genes detected in each set appears above the column. (B) Union of reported driver gene fusions represented as a percentage of total driver fusions present in the cohort (n = 164). Fusions reported by any of the fusion callers included in the set are considered. The percentage of driver genes detected in each set appears above the column. (C) Graph of total number of driver gene fusions detected by each fusion calling algorithm.</p>
        <p>(TIF)</p>
      </caption>
      <media xlink:href="pgen.1010300.s010.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <p>The authors would like to acknowledge the South Australian Genomics Centre (SAGC, SA, AUS) and the ACRF Cellular Imaging and Cytometry Core Facility (SAHMRI, SA, AUS) for sequencing and imaging services. We would like to acknowledge the New South Wales Ministry of Health-funded Luminesce Alliance for personnel support and the lab of Professor Charles Mullighan at St Jude Children’s Research Hospital for providing sequencing data for the validation cohort. Finally, we would like to thank the patients, their families and treating clinicians for their participation in this study.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="pgen.1010300.ref001">
      <label>1</label>
      <mixed-citation publication-type="journal"><name><surname>Coccaro</surname><given-names>N</given-names></name>, <name><surname>Anelli</surname><given-names>L</given-names></name>, <name><surname>Zagaria</surname><given-names>A</given-names></name>, <name><surname>Specchia</surname><given-names>G</given-names></name>, <name><surname>Albano</surname><given-names>F</given-names></name>. <article-title>Next-Generation Sequencing in Acute Lymphoblastic Leukemia.</article-title><source>Int J Mol Sci</source> [Internet]. <year>2019</year>
<month>Jun</month>
<day>15</day>;<volume>20</volume>(<issue>12</issue>). Available from: <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms20122929</pub-id>
<?supplied-pmid 31208040?><pub-id pub-id-type="pmid">31208040</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref002">
      <label>2</label>
      <mixed-citation publication-type="journal"><name><surname>Malard</surname><given-names>F</given-names></name>, <name><surname>Mohty</surname><given-names>M</given-names></name>. <article-title>Acute lymphoblastic leukaemia</article-title>. <source>Lancet</source>. <year>2020</year><month>Apr</month><day>4</day>;<volume>395</volume>(<issue>10230</issue>):<fpage>1146</fpage>–<lpage>62</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(19)33018-1</pub-id><?supplied-pmid 32247396?><pub-id pub-id-type="pmid">32247396</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref003">
      <label>3</label>
      <mixed-citation publication-type="journal"><name><surname>Yeung</surname><given-names>DTO</given-names></name>, <name><surname>Osborn</surname><given-names>MP</given-names></name>, <name><surname>White</surname><given-names>DL</given-names></name>. <article-title>B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification</article-title>. <source>Br J Haematol</source>. <year>2022</year><month>Apr</month>;<volume>197</volume>(<issue>1</issue>):<fpage>13</fpage>–<lpage>27</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/bjh.17879</pub-id><?supplied-pmid 34747016?><pub-id pub-id-type="pmid">34747016</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref004">
      <label>4</label>
      <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>JF</given-names></name>, <name><surname>Dai</surname><given-names>YT</given-names></name>, <name><surname>Lilljebjörn</surname><given-names>H</given-names></name>, <name><surname>Shen</surname><given-names>SH</given-names></name>, <name><surname>Cui</surname><given-names>BW</given-names></name>, <name><surname>Bai</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases</article-title>. <source>Proc Natl Acad Sci U S A</source> [Internet]. <year>2018</year>; Available from: <pub-id pub-id-type="doi">10.1073/pnas.1814397115</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref005">
      <label>5</label>
      <mixed-citation publication-type="journal"><name><surname>Gu</surname><given-names>Z</given-names></name>, <name><surname>Churchman</surname><given-names>ML</given-names></name>, <name><surname>Roberts</surname><given-names>KG</given-names></name>, <name><surname>Moore</surname><given-names>I</given-names></name>, <name><surname>Zhou</surname><given-names>X</given-names></name>, <name><surname>Nakitandwe</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia</article-title>. <source>Nat Genet</source>. <year>2019</year><month>Feb</month><day>14</day>;<volume>51</volume>(<issue>2</issue>):<fpage>296</fpage>–<lpage>307</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41588-018-0315-5</pub-id><?supplied-pmid 30643249?><pub-id pub-id-type="pmid">30643249</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref006">
      <label>6</label>
      <mixed-citation publication-type="journal"><name><surname>Zaliova</surname><given-names>M</given-names></name>, <name><surname>Stuchly</surname><given-names>J</given-names></name>, <name><surname>Winkowska</surname><given-names>L</given-names></name>, <name><surname>Musilova</surname><given-names>A</given-names></name>, <name><surname>Fiser</surname><given-names>K</given-names></name>, <name><surname>Slamova</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort</article-title>. <source>Haematologica</source>. <year>2019</year><month>Jul</month>;<volume>104</volume>(<issue>7</issue>):<fpage>1396</fpage>–<lpage>406</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3324/haematol.2018.204974</pub-id><?supplied-pmid 30630978?><pub-id pub-id-type="pmid">30630978</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref007">
      <label>7</label>
      <mixed-citation publication-type="journal"><name><surname>Tran</surname><given-names>TH</given-names></name>, <name><surname>Langlois</surname><given-names>S</given-names></name>, <name><surname>Meloche</surname><given-names>C</given-names></name>, <name><surname>Caron</surname><given-names>M</given-names></name>, <name><surname>Saint-Onge</surname><given-names>P</given-names></name>, <name><surname>Rouette</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16–001.</article-title><source>Blood Adv.</source><year>2022</year><month>Feb</month><day>22</day>;<volume>6</volume>(<issue>4</issue>):<fpage>1329</fpage>–<lpage>41</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/bloodadvances.2021005634</pub-id><?supplied-pmid 34933343?><pub-id pub-id-type="pmid">34933343</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref008">
      <label>8</label>
      <mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>KG</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Payne-Turner</surname><given-names>D</given-names></name>, <name><surname>Harvey</surname><given-names>RC</given-names></name>, <name><surname>Yang</surname><given-names>Y-L</given-names></name>, <name><surname>Pei</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia</article-title>. <source>N Engl J Med</source>. <year>2014</year><month>Sep</month><day>11</day>;<volume>371</volume>(<issue>11</issue>):<fpage>1005</fpage>–<lpage>15</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa1403088</pub-id><?supplied-pmid 25207766?><pub-id pub-id-type="pmid">25207766</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref009">
      <label>9</label>
      <mixed-citation publication-type="journal"><name><surname>Yeung</surname><given-names>DT</given-names></name>, <name><surname>Moulton</surname><given-names>DJ</given-names></name>, <name><surname>Heatley</surname><given-names>SL</given-names></name>, <name><surname>Nievergall</surname><given-names>E</given-names></name>, <name><surname>Dang</surname><given-names>P</given-names></name>, <name><surname>Braley</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment</article-title>. <source>Leukemia</source>. <year>2015</year><month>Jan</month>;<volume>29</volume>(<issue>1</issue>):<fpage>230</fpage>–<lpage>2</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/leu.2014.256</pub-id><?supplied-pmid 25179732?><pub-id pub-id-type="pmid">25179732</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref010">
      <label>10</label>
      <mixed-citation publication-type="journal"><name><surname>Harvey</surname><given-names>RC</given-names></name>, <name><surname>Mullighan</surname><given-names>CG</given-names></name>, <name><surname>Chen</surname><given-names>I-M</given-names></name>, <name><surname>Wharton</surname><given-names>W</given-names></name>, <name><surname>Mikhail</surname><given-names>FM</given-names></name>, <name><surname>Carroll</surname><given-names>AJ</given-names></name>, <etal>et al</etal>. <article-title>Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia</article-title>. <source>Blood</source>. <year>2010</year><month>Jul</month><day>1</day>;<volume>115</volume>(<issue>26</issue>):<fpage>5312</fpage>–<lpage>21</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood-2009-09-245944</pub-id><?supplied-pmid 20139093?><pub-id pub-id-type="pmid">20139093</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref011">
      <label>11</label>
      <mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>KG</given-names></name>, <name><surname>Morin</surname><given-names>RD</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Hirst</surname><given-names>M</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name>, <name><surname>Su</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia</article-title>. <source>Cancer Cell</source>. <year>2012</year><month>Aug</month><day>14</day>;<volume>22</volume>(<issue>2</issue>):<fpage>153</fpage>–<lpage>66</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ccr.2012.06.005</pub-id><?supplied-pmid 22897847?><pub-id pub-id-type="pmid">22897847</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref012">
      <label>12</label>
      <mixed-citation publication-type="journal"><name><surname>Iacobucci</surname><given-names>I</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Roberts</surname><given-names>KG</given-names></name>, <name><surname>Dobson</surname><given-names>SM</given-names></name>, <name><surname>Kim</surname><given-names>JC</given-names></name>, <name><surname>Payne-Turner</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia</article-title>. <source>Cancer Cell</source>. <year>2016</year><month>Feb</month><day>8</day>;<volume>29</volume>(<issue>2</issue>):<fpage>186</fpage>–<lpage>200</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ccell.2015.12.013</pub-id><?supplied-pmid 26859458?><pub-id pub-id-type="pmid">26859458</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref013">
      <label>13</label>
      <mixed-citation publication-type="journal"><name><surname>Yasuda</surname><given-names>T</given-names></name>, <name><surname>Tsuzuki</surname><given-names>S</given-names></name>, <name><surname>Kawazu</surname><given-names>M</given-names></name>, <name><surname>Hayakawa</surname><given-names>F</given-names></name>, <name><surname>Kojima</surname><given-names>S</given-names></name>, <name><surname>Ueno</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults</article-title>. <source>Nat Genet</source>. <year>2016</year><month>May</month>;<volume>48</volume>(<issue>5</issue>):<fpage>569</fpage>–<lpage>74</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ng.3535</pub-id><?supplied-pmid 27019113?><pub-id pub-id-type="pmid">27019113</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref014">
      <label>14</label>
      <mixed-citation publication-type="journal"><name><surname>Lilljebjörn</surname><given-names>H</given-names></name>, <name><surname>Henningsson</surname><given-names>R</given-names></name>, <name><surname>Hyrenius-Wittsten</surname><given-names>A</given-names></name>, <name><surname>Olsson</surname><given-names>L</given-names></name>, <name><surname>Orsmark-Pietras</surname><given-names>C</given-names></name>, <name><surname>von Palffy</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia.</article-title><source>Nat Commun.</source><year>2016</year><month>Dec</month><day>6</day>;<volume>7</volume>(<issue>1</issue>):<fpage>11790</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ncomms11790</pub-id><?supplied-pmid 27265895?><pub-id pub-id-type="pmid">27265895</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref015">
      <label>15</label>
      <mixed-citation publication-type="journal"><name><surname>Jerchel</surname><given-names>IS</given-names></name>, <name><surname>Hoogkamer</surname><given-names>AQ</given-names></name>, <name><surname>Ariës</surname><given-names>IM</given-names></name>, <name><surname>Steeghs</surname><given-names>EMP</given-names></name>, <name><surname>Boer</surname><given-names>JM</given-names></name>, <name><surname>Besselink</surname><given-names>NJM</given-names></name>, <etal>et al</etal>. <article-title>RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia</article-title>. <source>Leukemia</source>. <year>2018</year><month>Apr</month>;<volume>32</volume>(<issue>4</issue>):<fpage>931</fpage>–<lpage>40</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/leu.2017.303</pub-id><?supplied-pmid 28972594?><pub-id pub-id-type="pmid">28972594</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref016">
      <label>16</label>
      <mixed-citation publication-type="journal"><name><surname>Irving</surname><given-names>J</given-names></name>, <name><surname>Matheson</surname><given-names>E</given-names></name>, <name><surname>Minto</surname><given-names>L</given-names></name>, <name><surname>Blair</surname><given-names>H</given-names></name>, <name><surname>Case</surname><given-names>M</given-names></name>, <name><surname>Halsey</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition</article-title>. <source>Blood</source>. <year>2014</year><month>Nov</month><day>27</day>;<volume>124</volume>(<issue>23</issue>):<fpage>3420</fpage>–<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood-2014-04-531871</pub-id><?supplied-pmid 25253770?><pub-id pub-id-type="pmid">25253770</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref017">
      <label>17</label>
      <mixed-citation publication-type="journal"><name><surname>Sadras</surname><given-names>T</given-names></name>, <name><surname>Heatley</surname><given-names>SL</given-names></name>, <name><surname>Kok</surname><given-names>CH</given-names></name>, <name><surname>Dang</surname><given-names>P</given-names></name>, <name><surname>Galbraith</surname><given-names>KM</given-names></name>, <name><surname>McClure</surname><given-names>BJ</given-names></name>, <etal>et al</etal>. <article-title>Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions</article-title>. <source>Cancer Lett</source>. <year>2017</year><month>Nov</month><day>1</day>;<volume>408</volume>:<fpage>92</fpage>–<lpage>101</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.canlet.2017.08.034</pub-id><?supplied-pmid 28866095?><pub-id pub-id-type="pmid">28866095</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref018">
      <label>18</label>
      <mixed-citation publication-type="journal"><name><surname>Mullighan</surname><given-names>CG</given-names></name>, <name><surname>Collins-Underwood</surname><given-names>JR</given-names></name>, <name><surname>Phillips</surname><given-names>LAA</given-names></name>, <name><surname>Loudin</surname><given-names>MG</given-names></name>, <name><surname>Liu</surname><given-names>W</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Rearrangement of CRLF2 in B-progenitor-and Down syndrome-associated acute lymphoblastic leukemia.</article-title><source>Nat Genet</source> [Internet]. <year>2009</year>; Available from: <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ng.469</pub-id>
<?supplied-pmid 19838194?><pub-id pub-id-type="pmid">19838194</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref019">
      <label>19</label>
      <mixed-citation publication-type="journal"><name><surname>Mullighan</surname><given-names>CG</given-names></name>, <name><surname>Miller</surname><given-names>CB</given-names></name>, <name><surname>Radtke</surname><given-names>I</given-names></name>, <name><surname>Phillips</surname><given-names>LA</given-names></name>, <name><surname>Dalton</surname><given-names>J</given-names></name>, <name><surname>Ma</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros</article-title>. <source>Nature</source>. <year>2008</year><month>May</month><day>1</day>;<volume>453</volume>(<issue>7191</issue>):<fpage>110</fpage>–<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature06866</pub-id><?supplied-pmid 18408710?><pub-id pub-id-type="pmid">18408710</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref020">
      <label>20</label>
      <mixed-citation publication-type="journal"><name><surname>Dörge</surname><given-names>P</given-names></name>, <name><surname>Meissner</surname><given-names>B</given-names></name>, <name><surname>Zimmermann</surname><given-names>M</given-names></name>, <name><surname>Möricke</surname><given-names>A</given-names></name>, <name><surname>Schrauder</surname><given-names>A</given-names></name>, <name><surname>Bouquin</surname><given-names>J-P</given-names></name>, <etal>et al</etal>. <article-title>IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol</article-title>. <source>Haematologica</source>. <year>2013</year><month>Mar</month>;<volume>98</volume>(<issue>3</issue>):<fpage>428</fpage>–<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3324/haematol.2011.056135</pub-id><?supplied-pmid 22875627?><pub-id pub-id-type="pmid">22875627</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref021">
      <label>21</label>
      <mixed-citation publication-type="journal"><name><surname>Simonin</surname><given-names>M</given-names></name>, <name><surname>Lhermitte</surname><given-names>L</given-names></name>, <name><surname>Dourthe</surname><given-names>M-E</given-names></name>, <name><surname>Lengliné</surname><given-names>E</given-names></name>, <name><surname>Graux</surname><given-names>C</given-names></name>, <name><surname>Grardel</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL</article-title>. <source>Blood</source>. <year>2021</year><month>Mar</month><day>25</day>;<volume>137</volume>(<issue>12</issue>):<fpage>1690</fpage>–<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood.2020007959</pub-id><?supplied-pmid 33150353?><pub-id pub-id-type="pmid">33150353</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref022">
      <label>22</label>
      <mixed-citation publication-type="journal"><name><surname>Harvey</surname><given-names>RC</given-names></name>, <name><surname>Tasian</surname><given-names>SK</given-names></name>. <article-title>Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia</article-title>. <source>Blood Adv</source>. <year>2020</year><month>Jan</month><day>14</day>;<volume>4</volume>(<issue>1</issue>):<fpage>218</fpage>–<lpage>28</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/bloodadvances.2019000163</pub-id><?supplied-pmid 31935290?><pub-id pub-id-type="pmid">31935290</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref023">
      <label>23</label>
      <mixed-citation publication-type="journal"><name><surname>Uhrig</surname><given-names>S</given-names></name>, <name><surname>Ellermann</surname><given-names>J</given-names></name>, <name><surname>Walther</surname><given-names>T</given-names></name>, <name><surname>Burkhardt</surname><given-names>P</given-names></name>, <name><surname>Fröhlich</surname><given-names>M</given-names></name>, <name><surname>Hutter</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Accurate and efficient detection of gene fusions from RNA sequencing data</article-title>. <source>Genome Res</source>. <year>2021</year><month>Mar</month>;<volume>31</volume>(<issue>3</issue>):<fpage>448</fpage>–<lpage>60</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/gr.257246.119</pub-id><?supplied-pmid 33441414?><pub-id pub-id-type="pmid">33441414</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref024">
      <label>24</label>
      <mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>LM</given-names></name>, <name><surname>Lonsdale</surname><given-names>A</given-names></name>, <name><surname>Zhu</surname><given-names>A</given-names></name>, <name><surname>Davidson</surname><given-names>NM</given-names></name>, <name><surname>Schmidt</surname><given-names>B</given-names></name>, <name><surname>Hawkins</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia</article-title>. <source>Blood Adv</source>. <year>2020</year><month>Mar</month><day>10</day>;<volume>4</volume>(<issue>5</issue>):<fpage>930</fpage>–<lpage>42</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/bloodadvances.2019001008</pub-id><?supplied-pmid 32150610?><pub-id pub-id-type="pmid">32150610</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref025">
      <label>25</label>
      <mixed-citation publication-type="journal"><name><surname>Tian</surname><given-names>L</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Edmonson</surname><given-names>MN</given-names></name>, <name><surname>Zhou</surname><given-names>X</given-names></name>, <name><surname>Newman</surname><given-names>S</given-names></name>, <name><surname>McLeod</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>CICERO: a versatile method for detecting complex and diverse driver fusions using cancer RNA sequencing data</article-title>. <source>Genome Biol</source>. <year>2020</year><month>May</month><day>28</day>;<volume>21</volume>(<issue>1</issue>):<fpage>126</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13059-020-02043-x</pub-id><?supplied-pmid 32466770?><pub-id pub-id-type="pmid">32466770</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref026">
      <label>26</label>
      <mixed-citation publication-type="journal"><name><surname>Haas</surname><given-names>BJ</given-names></name>, <name><surname>Dobin</surname><given-names>A</given-names></name>, <name><surname>Stransky</surname><given-names>N</given-names></name>, <name><surname>Li</surname><given-names>B</given-names></name>, <name><surname>Yang</surname><given-names>X</given-names></name>, <name><surname>Tickle</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>STAR-Fusion: Fast and Accurate Fusion Transcript Detection from RNA-Seq [Internet].</article-title><source>bioRxiv</source>. <year>2017</year> [cited 2021 Jun 17]. p. <fpage>120295</fpage>. Available from: <ext-link xlink:href="https://www.biorxiv.org/content/10.1101/120295v1" ext-link-type="uri">https://www.biorxiv.org/content/10.1101/120295v1</ext-link></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref027">
      <label>27</label>
      <mixed-citation publication-type="journal"><name><surname>Haas</surname><given-names>BJ</given-names></name>, <name><surname>Dobin</surname><given-names>A</given-names></name>, <name><surname>Li</surname><given-names>B</given-names></name>, <name><surname>Stransky</surname><given-names>N</given-names></name>, <name><surname>Pochet</surname><given-names>N</given-names></name>, <name><surname>Regev</surname><given-names>A</given-names></name>. <article-title>Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods</article-title>. <source>Genome Biol</source>. <year>2019</year><month>Oct</month><day>21</day>;<volume>20</volume>(<issue>1</issue>):<fpage>213</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13059-019-1842-9</pub-id><?supplied-pmid 31639029?><pub-id pub-id-type="pmid">31639029</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref028">
      <label>28</label>
      <mixed-citation publication-type="journal"><name><surname>Audemard</surname><given-names>EO</given-names></name>, <name><surname>Gendron</surname><given-names>P</given-names></name>, <name><surname>Feghaly</surname><given-names>A</given-names></name>, <name><surname>Lavallée</surname><given-names>V-P</given-names></name>, <name><surname>Hébert</surname><given-names>J</given-names></name>, <name><surname>Sauvageau</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Targeted variant detection using unaligned RNA-Seq reads</article-title>. <source>Life Sci Alliance</source> [Internet]. <year>2019</year>
<month>Aug</month>;<volume>2</volume>(<issue>4</issue>). Available from: <comment>doi: </comment><pub-id pub-id-type="doi">10.26508/lsa.201900336</pub-id>
<?supplied-pmid 31427380?><pub-id pub-id-type="pmid">31427380</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref029">
      <label>29</label>
      <mixed-citation publication-type="journal"><name><surname>Van der Auwera</surname><given-names>GA</given-names></name>, <name><surname>Carneiro</surname><given-names>MO</given-names></name>, <name><surname>Hartl</surname><given-names>C</given-names></name>, <name><surname>Poplin</surname><given-names>R</given-names></name>, <name><surname>Del Angel</surname><given-names>G</given-names></name>, <name><surname>Levy-Moonshine</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline</article-title>. <source>Curr Protoc Bioinformatics</source>. <year>2013</year>;<volume>43</volume>:11.10.1–11.10.33. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/0471250953.bi1110s43</pub-id><?supplied-pmid 25431634?><pub-id pub-id-type="pmid">25431634</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref030">
      <label>30</label>
      <mixed-citation publication-type="journal"><name><surname>Nicorici</surname><given-names>D</given-names></name>, <name><surname>Şatalan</surname><given-names>M</given-names></name>, <name><surname>Edgren</surname><given-names>H</given-names></name>, <name><surname>Kangaspeska</surname><given-names>S</given-names></name>, <name><surname>Murumägi</surname><given-names>A</given-names></name>, <name><surname>Kallioniemi</surname><given-names>O</given-names></name>, <etal>et al</etal>. <article-title>FusionCatcher–a tool for finding somatic fusion genes in paired-end RNA-sequencing data.</article-title><source>bioRxiv</source>. <year>2014</year><month>Nov</month><day>19</day>;<fpage>011650</fpage>.</mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref031">
      <label>31</label>
      <mixed-citation publication-type="journal"><name><surname>Jia</surname><given-names>W</given-names></name>, <name><surname>Qiu</surname><given-names>K</given-names></name>, <name><surname>He</surname><given-names>M</given-names></name>, <name><surname>Song</surname><given-names>P</given-names></name>, <name><surname>Zhou</surname><given-names>Q</given-names></name>, <name><surname>Zhou</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>SOAPfuse: an algorithm for identifying fusion transcripts from paired-end RNA-Seq data</article-title>. <source>Genome Biol</source>. <year>2013</year><month>Feb</month><day>14</day>;<volume>14</volume>(<issue>2</issue>):<fpage>R12</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/gb-2013-14-2-r12</pub-id><?supplied-pmid 23409703?><pub-id pub-id-type="pmid">23409703</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref032">
      <label>32</label>
      <mixed-citation publication-type="journal"><name><surname>Davidson</surname><given-names>NM</given-names></name>, <name><surname>Majewski</surname><given-names>IJ</given-names></name>, <name><surname>Oshlack</surname><given-names>A</given-names></name>. <article-title>JAFFA: High sensitivity transcriptome-focused fusion gene detection.</article-title><source>Genome Med</source>. <year>2015</year><month>Dec</month><day>11</day>;<volume>7</volume>(<issue>1</issue>):<fpage>43</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13073-015-0167-x</pub-id><?supplied-pmid 26019724?><pub-id pub-id-type="pmid">26019724</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref033">
      <label>33</label>
      <mixed-citation publication-type="journal"><name><surname>Marçais</surname><given-names>G</given-names></name>, <name><surname>Kingsford</surname><given-names>C</given-names></name>. <article-title>A fast, lock-free approach for efficient parallel counting of occurrences of k-mers.</article-title><source>Bioinformatics</source>. <year>2011</year><month>Mar</month><day>15</day>;<volume>27</volume>(<issue>6</issue>):<fpage>764</fpage>–<lpage>70</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btr011</pub-id><?supplied-pmid 21217122?><pub-id pub-id-type="pmid">21217122</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref034">
      <label>34</label>
      <mixed-citation publication-type="journal"><name><surname>Manekar</surname><given-names>SC</given-names></name>, <name><surname>Sathe</surname><given-names>SR</given-names></name>. <article-title>A benchmark study of k-mer counting methods for high-throughput sequencing.</article-title><source>Gigascience</source> [Internet]. <year>2018</year>
<month>Dec</month>
<day>1</day>;<volume>7</volume>(<issue>12</issue>). Available from: <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/gigascience/giy125</pub-id>
<?supplied-pmid 30346548?><pub-id pub-id-type="pmid">30346548</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref035">
      <label>35</label>
      <mixed-citation publication-type="journal"><name><surname>Langmead</surname><given-names>B</given-names></name>, <name><surname>Nellore</surname><given-names>A</given-names></name>. <article-title>Cloud computing for genomic data analysis and collaboration</article-title>. <source>Nat Rev Genet</source>. <year>2018</year><month>Apr</month>;<volume>19</volume>(<issue>4</issue>):<fpage>208</fpage>–<lpage>19</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrg.2017.113</pub-id><?supplied-pmid 29379135?><pub-id pub-id-type="pmid">29379135</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref036">
      <label>36</label>
      <mixed-citation publication-type="journal"><name><surname>Stanulla</surname><given-names>M</given-names></name>, <name><surname>Cavé</surname><given-names>H</given-names></name>, <name><surname>Moorman</surname><given-names>AV</given-names></name>. <article-title>IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?</article-title><source>Blood</source>. <year>2020</year><month>Jan</month><day>23</day>;<volume>135</volume>(<issue>4</issue>):<fpage>252</fpage>–<lpage>60</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood.2019000813</pub-id><?supplied-pmid 31821407?><pub-id pub-id-type="pmid">31821407</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref037">
      <label>37</label>
      <mixed-citation publication-type="journal"><name><surname>Mullighan</surname><given-names>CG</given-names></name>, <name><surname>Su</surname><given-names>X</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Radtke</surname><given-names>I</given-names></name>, <name><surname>Phillips</surname><given-names>LAA</given-names></name>, <name><surname>Miller</surname><given-names>CB</given-names></name>, <etal>et al</etal>. <article-title>Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia</article-title>. <source>N Engl J Med</source>. <year>2009</year><month>Jan</month><day>29</day>;<volume>360</volume>(<issue>5</issue>):<fpage>470</fpage>–<lpage>80</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa0808253</pub-id><?supplied-pmid 19129520?><pub-id pub-id-type="pmid">19129520</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref038">
      <label>38</label>
      <mixed-citation publication-type="journal"><name><surname>Stanulla</surname><given-names>M</given-names></name>, <name><surname>Dagdan</surname><given-names>E</given-names></name>, <name><surname>Zaliova</surname><given-names>M</given-names></name>, <name><surname>Möricke</surname><given-names>A</given-names></name>, <name><surname>Palmi</surname><given-names>C</given-names></name>, <name><surname>Cazzaniga</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.</article-title><source>J Clin Oncol</source>. <year>2018</year>;<volume>36</volume>(<issue>12</issue>):<fpage>1240</fpage>–<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1200/JCO.2017.74.3617</pub-id><?supplied-pmid 29498923?><pub-id pub-id-type="pmid">29498923</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref039">
      <label>39</label>
      <mixed-citation publication-type="journal"><name><surname>Hamadeh</surname><given-names>L</given-names></name>, <name><surname>Enshaei</surname><given-names>A</given-names></name>, <name><surname>Schwab</surname><given-names>C</given-names></name>, <name><surname>Alonso</surname><given-names>CN</given-names></name>, <name><surname>Attarbaschi</surname><given-names>A</given-names></name>, <name><surname>Barbany</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL</article-title>. <source>Blood advances</source>. <year>2019</year><month>Jan</month><day>22</day>;<volume>3</volume>(<issue>2</issue>):<fpage>148</fpage>–<lpage>57</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/bloodadvances.2018025718</pub-id><?supplied-pmid 30651283?><pub-id pub-id-type="pmid">30651283</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref040">
      <label>40</label>
      <mixed-citation publication-type="journal"><name><surname>Shanmuganathan</surname><given-names>N</given-names></name>, <name><surname>Thomson</surname><given-names>D</given-names></name>, <name><surname>Wadham</surname><given-names>C</given-names></name>, <name><surname>Saunders</surname><given-names>VA</given-names></name>, <name><surname>Shahrin</surname><given-names>NH</given-names></name>, <name><surname>Yeung</surname><given-names>DT</given-names></name>, <etal>et al</etal>. <article-title>RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML</article-title>. <source>Blood</source>. <year>2019</year><month>Nov</month><day>13</day>;<volume>134</volume>:<fpage>662</fpage>.</mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref041">
      <label>41</label>
      <mixed-citation publication-type="journal"><name><surname>Passet</surname><given-names>M</given-names></name>, <name><surname>Boissel</surname><given-names>N</given-names></name>, <name><surname>Sigaux</surname><given-names>F</given-names></name>, <name><surname>Saillard</surname><given-names>C</given-names></name>, <name><surname>Bargetzi</surname><given-names>M</given-names></name>, <name><surname>Ba</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome</article-title>. <source>Blood</source>. <year>2019</year><month>Jan</month><day>17</day>;<volume>133</volume>(<issue>3</issue>):<fpage>280</fpage>–<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood-2018-10-882142</pub-id><?supplied-pmid 30510083?><pub-id pub-id-type="pmid">30510083</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref042">
      <label>42</label>
      <mixed-citation publication-type="journal"><name><surname>Safavi</surname><given-names>S</given-names></name>, <name><surname>Olsson</surname><given-names>L</given-names></name>, <name><surname>Biloglav</surname><given-names>A</given-names></name>, <name><surname>Veerla</surname><given-names>S</given-names></name>, <name><surname>Blendberg</surname><given-names>M</given-names></name>, <name><surname>Tayebwa</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Genetic and epigenetic characterization of hypodiploid acute lymphoblastic leukemia</article-title>. <source>Oncotarget</source>. <year>2015</year><month>Dec</month><day>15</day>;<volume>6</volume>(<issue>40</issue>):<fpage>42793</fpage>–<lpage>802</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.18632/oncotarget.6000</pub-id><?supplied-pmid 26544893?><pub-id pub-id-type="pmid">26544893</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref043">
      <label>43</label>
      <mixed-citation publication-type="journal"><name><surname>Holmfeldt</surname><given-names>L</given-names></name>, <name><surname>Wei</surname><given-names>L</given-names></name>, <name><surname>Diaz-Flores</surname><given-names>E</given-names></name>, <name><surname>Walsh</surname><given-names>M</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Ding</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>The genomic landscape of hypodiploid acute lymphoblastic leukemia</article-title>. <source>Nat Genet</source>. <year>2013</year><month>Mar</month>;<volume>45</volume>(<issue>3</issue>):<fpage>242</fpage>–<lpage>52</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ng.2532</pub-id><?supplied-pmid 23334668?><pub-id pub-id-type="pmid">23334668</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref044">
      <label>44</label>
      <mixed-citation publication-type="journal"><name><surname>Yoda</surname><given-names>A</given-names></name>, <name><surname>Yoda</surname><given-names>Y</given-names></name>, <name><surname>Chiaretti</surname><given-names>S</given-names></name>, <name><surname>Bar-Natan</surname><given-names>M</given-names></name>, <name><surname>Mani</surname><given-names>K</given-names></name>, <name><surname>Rodig</surname><given-names>SJ</given-names></name>, <etal>et al</etal>. <article-title>Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2010</year><month>Jan</month><day>5</day>;<volume>107</volume>(<issue>1</issue>):<fpage>252</fpage>–<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.0911726107</pub-id><?supplied-pmid 20018760?><pub-id pub-id-type="pmid">20018760</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref045">
      <label>45</label>
      <mixed-citation publication-type="journal"><name><surname>Mullighan</surname><given-names>CG</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Harvey</surname><given-names>RC</given-names></name>, <name><surname>Collins-Underwood</surname><given-names>JR</given-names></name>, <name><surname>Schulman</surname><given-names>BA</given-names></name>, <name><surname>Phillips</surname><given-names>LA</given-names></name>, <etal>et al</etal>. <article-title>JAK mutations in high-risk childhood acute lymphoblastic leukemia</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2009</year><month>Jun</month><day>9</day>;<volume>106</volume>(<issue>23</issue>):<fpage>9414</fpage>–<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.0811761106</pub-id><?supplied-pmid 19470474?><pub-id pub-id-type="pmid">19470474</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref046">
      <label>46</label>
      <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>C</given-names></name>, <name><surname>Li</surname><given-names>F</given-names></name>, <name><surname>Ma</surname><given-names>M-M</given-names></name>, <name><surname>Zhang</surname><given-names>S</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Yan</surname><given-names>Z-L</given-names></name>, <etal>et al</etal>. <article-title>Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells</article-title>. <source>Int J Biol Macromol</source>. <year>2019</year><month>Sep</month><day>15</day>;<volume>137</volume>:<fpage>1030</fpage>–<lpage>40</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2019.07.065</pub-id><?supplied-pmid 31299252?><pub-id pub-id-type="pmid">31299252</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref047">
      <label>47</label>
      <mixed-citation publication-type="journal"><name><surname>Sadras</surname><given-names>T</given-names></name>, <name><surname>Heatley</surname><given-names>SL</given-names></name>, <name><surname>Kok</surname><given-names>CH</given-names></name>, <name><surname>McClure</surname><given-names>BJ</given-names></name>, <name><surname>Yeung</surname><given-names>D</given-names></name>, <name><surname>Hughes</surname><given-names>TP</given-names></name>, <etal>et al</etal>. <article-title>A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.</article-title><source>Cancer Genet</source>. <year>2017</year><month>Oct</month>;<volume>216–217</volume>:<fpage>86</fpage>–<lpage>90</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cancergen.2017.07.008</pub-id><?supplied-pmid 29025600?><pub-id pub-id-type="pmid">29025600</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref048">
      <label>48</label>
      <mixed-citation publication-type="journal"><name><surname>Irving</surname><given-names>JAE</given-names></name>, <name><surname>Enshaei</surname><given-names>A</given-names></name>, <name><surname>Parker</surname><given-names>CA</given-names></name>, <name><surname>Sutton</surname><given-names>R</given-names></name>, <name><surname>Kuiper</surname><given-names>RP</given-names></name>, <name><surname>Erhorn</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia</article-title>. <source>Blood</source>. <year>2016</year><month>Aug</month><day>18</day>;<volume>128</volume>(<issue>7</issue>):<fpage>911</fpage>–<lpage>22</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood-2016-03-704973</pub-id><?supplied-pmid 27229005?><pub-id pub-id-type="pmid">27229005</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref049">
      <label>49</label>
      <mixed-citation publication-type="journal"><name><surname>Forero-Castro</surname><given-names>M</given-names></name>, <name><surname>Robledo</surname><given-names>C</given-names></name>, <name><surname>Benito</surname><given-names>R</given-names></name>, <name><surname>Bodega-Mayor</surname><given-names>I</given-names></name>, <name><surname>Rapado</surname><given-names>I</given-names></name>, <name><surname>Hernández-Sánchez</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia</article-title>. <source>Br J Cancer</source>. <year>2017</year><month>Jul</month><day>11</day>;<volume>117</volume>(<issue>2</issue>):<fpage>256</fpage>–<lpage>65</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/bjc.2017.152</pub-id><?supplied-pmid 28557976?><pub-id pub-id-type="pmid">28557976</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref050">
      <label>50</label>
      <mixed-citation publication-type="journal"><name><surname>Stasevich</surname><given-names>I</given-names></name>, <name><surname>Inglott</surname><given-names>S</given-names></name>, <name><surname>Austin</surname><given-names>N</given-names></name>, <name><surname>Chatters</surname><given-names>S</given-names></name>, <name><surname>Chalker</surname><given-names>J</given-names></name>, <name><surname>Addy</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>PAX5 alterations in genetically unclassified childhood Precursor B-cell acute lymphoblastic leukaemia</article-title>. <source>Br J Haematol</source>. <year>2015</year><month>Oct</month>;<volume>171</volume>(<issue>2</issue>):<fpage>263</fpage>–<lpage>72</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/bjh.13543</pub-id><?supplied-pmid 26115422?><pub-id pub-id-type="pmid">26115422</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref051">
      <label>51</label>
      <mixed-citation publication-type="journal"><name><surname>Steeghs</surname><given-names>EMP</given-names></name>, <name><surname>Jerchel</surname><given-names>IS</given-names></name>, <name><surname>de Goffau-Nobel</surname><given-names>W</given-names></name>, <name><surname>Hoogkamer</surname><given-names>AQ</given-names></name>, <name><surname>Boer</surname><given-names>JM</given-names></name>, <name><surname>Boeree</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia</article-title>. <source>Oncotarget</source>. <year>2017</year><month>Oct</month><day>27</day>;<volume>8</volume>(<issue>52</issue>):<fpage>89923</fpage>–<lpage>38</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.18632/oncotarget.21027</pub-id><?supplied-pmid 29163799?><pub-id pub-id-type="pmid">29163799</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref052">
      <label>52</label>
      <mixed-citation publication-type="journal"><name><surname>Gu</surname><given-names>Z</given-names></name>, <name><surname>Churchman</surname><given-names>M</given-names></name>, <name><surname>Roberts</surname><given-names>K</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Harvey</surname><given-names>RC</given-names></name>, <etal>et al</etal>. <article-title>Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.</article-title><source>Nat Commun.</source><year>2016</year><month>Nov</month><source>8</source>;<volume>7</volume>:<fpage>13331</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ncomms13331</pub-id><?supplied-pmid 27824051?><pub-id pub-id-type="pmid">27824051</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref053">
      <label>53</label>
      <mixed-citation publication-type="journal"><name><surname>Hirabayashi</surname><given-names>S</given-names></name>, <name><surname>Ohki</surname><given-names>K</given-names></name>, <name><surname>Nakabayashi</surname><given-names>K</given-names></name>, <name><surname>Ichikawa</surname><given-names>H</given-names></name>, <name><surname>Momozawa</surname><given-names>Y</given-names></name>, <name><surname>Okamura</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype</article-title>. <source>Haematologica</source>. <year>2017</year><month>Jan</month>;<volume>102</volume>(<issue>1</issue>):<fpage>118</fpage>–<lpage>29</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3324/haematol.2016.151035</pub-id><?supplied-pmid 27634205?><pub-id pub-id-type="pmid">27634205</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref054">
      <label>54</label>
      <mixed-citation publication-type="journal"><name><surname>Gocho</surname><given-names>Y</given-names></name>, <name><surname>Kiyokawa</surname><given-names>N</given-names></name>, <name><surname>Ichikawa</surname><given-names>H</given-names></name>, <name><surname>Nakabayashi</surname><given-names>K</given-names></name>, <name><surname>Osumi</surname><given-names>T</given-names></name>, <name><surname>Ishibashi</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia</article-title>. <source>Leukemia</source>. <year>2015</year><month>Dec</month>;<volume>29</volume>(<issue>12</issue>):<fpage>2445</fpage>–<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/leu.2015.111</pub-id><?supplied-pmid 25943178?><pub-id pub-id-type="pmid">25943178</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref055">
      <label>55</label>
      <mixed-citation publication-type="journal"><name><surname>Peterson</surname><given-names>JF</given-names></name>, <name><surname>Smoley</surname><given-names>SA</given-names></name>, <name><surname>Luoma</surname><given-names>IM</given-names></name>, <name><surname>Pitel</surname><given-names>BA</given-names></name>, <name><surname>Rice</surname><given-names>CS</given-names></name>, <name><surname>Benevides Demasi</surname><given-names>JC</given-names></name>, <etal>et al</etal>. <article-title>Characterization of a cryptic KMT2A/AFF1 gene fusion by mate-pair sequencing (MPseq) in a young adult with newly diagnosed B-lymphoblastic leukemia.</article-title><source>J Hematop</source>. <year>2019</year><month>Jun</month><day>1</day>;<volume>12</volume>(<issue>2</issue>):<fpage>99</fpage>–<lpage>104</lpage>.</mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref056">
      <label>56</label>
      <mixed-citation publication-type="journal"><name><surname>Engvall</surname><given-names>M</given-names></name>, <name><surname>Cahill</surname><given-names>N</given-names></name>, <name><surname>Jonsson</surname><given-names>B-I</given-names></name>, <name><surname>Höglund</surname><given-names>M</given-names></name>, <name><surname>Hallböök</surname><given-names>H</given-names></name>, <name><surname>Cavelier</surname><given-names>L</given-names></name>. <article-title>Detection of leukemia gene fusions by targeted RNA-sequencing in routine diagnostics</article-title>. <source>BMC Med Genomics</source>. <year>2020</year><month>Jul</month><day>29</day>;<volume>13</volume>(<issue>1</issue>):<fpage>106</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12920-020-00739-4</pub-id><?supplied-pmid 32727569?><pub-id pub-id-type="pmid">32727569</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref057">
      <label>57</label>
      <mixed-citation publication-type="journal"><name><surname>Afrin</surname><given-names>S</given-names></name>, <name><surname>Zhang</surname><given-names>CRC</given-names></name>, <name><surname>Meyer</surname><given-names>C</given-names></name>, <name><surname>Stinson</surname><given-names>CL</given-names></name>, <name><surname>Pham</surname><given-names>T</given-names></name>, <name><surname>Bruxner</surname><given-names>TJC</given-names></name>, <etal>et al</etal>. <article-title>Targeted Next-Generation Sequencing for Detecting MLL Gene Fusions in Leukemia</article-title>. <source>Mol Cancer Res</source>. <year>2018</year><month>Feb</month>;<volume>16</volume>(<issue>2</issue>):<fpage>279</fpage>–<lpage>85</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-17-0569</pub-id><?supplied-pmid 29133595?><pub-id pub-id-type="pmid">29133595</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref058">
      <label>58</label>
      <mixed-citation publication-type="journal"><name><surname>Meyer</surname><given-names>C</given-names></name>, <name><surname>Burmeister</surname><given-names>T</given-names></name>, <name><surname>Strehl</surname><given-names>S</given-names></name>, <name><surname>Schneider</surname><given-names>B</given-names></name>, <name><surname>Hubert</surname><given-names>D</given-names></name>, <name><surname>Zach</surname><given-names>O</given-names></name>, <etal>et al</etal>. <article-title>Spliced MLL fusions: a novel mechanism to generate functional chimeric MLL-MLLT1 transcripts in t(11,19)(q23;p13.3) leukemia.</article-title><source>Leukemia</source>. <year>2007</year><month>Mar</month>;<volume>21</volume>(<issue>3</issue>):<fpage>588</fpage>–<lpage>90</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/sj.leu.2404542</pub-id><?supplied-pmid 17252016?><pub-id pub-id-type="pmid">17252016</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref059">
      <label>59</label>
      <mixed-citation publication-type="journal"><name><surname>De Braekeleer</surname><given-names>E</given-names></name>, <name><surname>Douet-Guilbert</surname><given-names>N</given-names></name>, <name><surname>Rowe</surname><given-names>D</given-names></name>, <name><surname>Bown</surname><given-names>N</given-names></name>, <name><surname>Morel</surname><given-names>F</given-names></name>, <name><surname>Berthou</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>ABL1 fusion genes in hematological malignancies: a review</article-title>. <source>Eur J Haematol</source>. <year>2011</year><month>May</month>;<volume>86</volume>(<issue>5</issue>):<fpage>361</fpage>–<lpage>71</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1600-0609.2011.01586.x</pub-id><?supplied-pmid 21435002?><pub-id pub-id-type="pmid">21435002</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref060">
      <label>60</label>
      <mixed-citation publication-type="journal"><name><surname>Schwab</surname><given-names>C</given-names></name>, <name><surname>Roberts</surname><given-names>K</given-names></name>, <name><surname>Boer</surname><given-names>JM</given-names></name>, <name><surname>Göhring</surname><given-names>G</given-names></name>, <name><surname>Steinemann</surname><given-names>D</given-names></name>, <name><surname>Vora</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome</article-title>. <source>Blood</source>. <year>2021</year><month>Apr</month><day>1</day>;<volume>137</volume>(<issue>13</issue>):<fpage>1835</fpage>–<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood.2020008536</pub-id><?supplied-pmid 33197935?><pub-id pub-id-type="pmid">33197935</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref061">
      <label>61</label>
      <mixed-citation publication-type="journal"><name><surname>Shago</surname><given-names>M</given-names></name>, <name><surname>Abla</surname><given-names>O</given-names></name>, <name><surname>Hitzler</surname><given-names>J</given-names></name>, <name><surname>Weitzman</surname><given-names>S</given-names></name>, <name><surname>Abdelhaleem</surname><given-names>M</given-names></name>. <article-title>Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion.</article-title><source>Pediatr Blood Cancer.</source><year>2016</year><month>Nov</month>;<volume>63</volume>(<issue>11</issue>):<fpage>1915</fpage>–<lpage>21</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/pbc.26116</pub-id><?supplied-pmid 27392123?><pub-id pub-id-type="pmid">27392123</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref062">
      <label>62</label>
      <mixed-citation publication-type="journal"><name><surname>Martini</surname><given-names>A</given-names></name>, <name><surname>La Starza</surname><given-names>R</given-names></name>, <name><surname>Janssen</surname><given-names>H</given-names></name>, <name><surname>Bilhou-Nabera</surname><given-names>C</given-names></name>, <name><surname>Corveleyn</surname><given-names>A</given-names></name>, <name><surname>Somers</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Recurrent rearrangement of the Ewing’s sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia</article-title>. <source>Cancer Res</source>. <year>2002</year><month>Oct</month><day>1</day>;<volume>62</volume>(<issue>19</issue>):<fpage>5408</fpage>–<lpage>12</lpage>. <?supplied-pmid 12359745?><pub-id pub-id-type="pmid">12359745</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref063">
      <label>63</label>
      <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>G</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Wu</surname><given-names>J</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Ma</surname><given-names>Z</given-names></name>. <article-title>Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.</article-title><source>Am J Case Rep.</source><year>2017</year><month>Nov</month><day>14</day>;<volume>18</volume>:<fpage>1204</fpage>–<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.12659/ajcr.906300</pub-id><?supplied-pmid 29133777?><pub-id pub-id-type="pmid">29133777</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref064">
      <label>64</label>
      <mixed-citation publication-type="journal"><name><surname>Kobayashi</surname><given-names>K</given-names></name>, <name><surname>Mitsui</surname><given-names>K</given-names></name>, <name><surname>Ichikawa</surname><given-names>H</given-names></name>, <name><surname>Nakabayashi</surname><given-names>K</given-names></name>, <name><surname>Matsuoka</surname><given-names>M</given-names></name>, <name><surname>Kojima</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children</article-title>. <source>Br J Haematol</source>. <year>2014</year><month>Jun</month>;<volume>165</volume>(<issue>6</issue>):<fpage>836</fpage>–<lpage>41</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/bjh.12834</pub-id><?supplied-pmid 24628626?><pub-id pub-id-type="pmid">24628626</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref065">
      <label>65</label>
      <mixed-citation publication-type="journal"><name><surname>Panagopoulos</surname><given-names>I</given-names></name>, <name><surname>Micci</surname><given-names>F</given-names></name>, <name><surname>Thorsen</surname><given-names>J</given-names></name>, <name><surname>Haugom</surname><given-names>L</given-names></name>, <name><surname>Tierens</surname><given-names>A</given-names></name>, <name><surname>Ulvmoen</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>A novel TCF3-HLF fusion transcript in acute lymphoblastic leukemia with a t(17,19)(q22;p13).</article-title><source>Cancer Genet.</source><year>2012</year><month>Dec</month>;<volume>205</volume>(<issue>12</issue>):<fpage>669</fpage>–<lpage>72</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cancergen.2012.10.004</pub-id><?supplied-pmid 23181981?><pub-id pub-id-type="pmid">23181981</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref066">
      <label>66</label>
      <mixed-citation publication-type="journal"><name><surname>Hein</surname><given-names>D</given-names></name>, <name><surname>Dreisig</surname><given-names>K</given-names></name>, <name><surname>Metzler</surname><given-names>M</given-names></name>, <name><surname>Izraeli</surname><given-names>S</given-names></name>, <name><surname>Schmiegelow</surname><given-names>K</given-names></name>, <name><surname>Borkhardt</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns</article-title>. <source>Blood</source>. <year>2019</year><month>Oct</month><day>17</day>;<volume>134</volume>(<issue>16</issue>):<fpage>1355</fpage>–<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood.2019002215</pub-id><?supplied-pmid 31434706?><pub-id pub-id-type="pmid">31434706</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref067">
      <label>67</label>
      <mixed-citation publication-type="journal"><name><surname>Yamamoto</surname><given-names>K</given-names></name>, <name><surname>Yakushijin</surname><given-names>K</given-names></name>, <name><surname>Mizutani</surname><given-names>Y</given-names></name>, <name><surname>Okuni-Watanabe</surname><given-names>M</given-names></name>, <name><surname>Goto</surname><given-names>H</given-names></name>, <name><surname>Higashime</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Expression of a novel type of KMT2A/EPS15 fusion transcript in FLT3 mutation-positive B-lymphoblastic leukemia with t(1,11)(p32;q23).</article-title><source>Cancer Genet.</source><year>2021</year><month>Jun</month>;<volume>254–255</volume>:<fpage>92</fpage>–<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cancergen.2021.02.006</pub-id><?supplied-pmid 33647817?><pub-id pub-id-type="pmid">33647817</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref068">
      <label>68</label>
      <mixed-citation publication-type="journal"><name><surname>Ni Chin</surname><given-names>WH</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Jiang</surname><given-names>N</given-names></name>, <name><surname>Lim</surname><given-names>EH</given-names></name>, <name><surname>Suang Lim</surname><given-names>JY</given-names></name>, <name><surname>Lu</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Practical Considerations for Using RNA Sequencing in Management of B-Lymphoblastic Leukemia: Malaysia-Singapore Acute Lymphoblastic Leukemia 2020</article-title><source>Implementation Strategy. J Mol Diagn</source>. <year>2021</year><month>Oct</month>;<volume>23</volume>(<issue>10</issue>):<fpage>1359</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">34365011</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref069">
      <label>69</label>
      <mixed-citation publication-type="journal"><collab>1000 Genomes Project Consortium</collab>, <name><surname>Auton</surname><given-names>A</given-names></name>, <name><surname>Brooks</surname><given-names>LD</given-names></name>, <name><surname>Durbin</surname><given-names>RM</given-names></name>, <name><surname>Garrison</surname><given-names>EP</given-names></name>, <name><surname>Kang</surname><given-names>HM</given-names></name>, <etal>et al</etal>. <article-title>A global reference for human genetic variation</article-title>. <source>Nature</source>. <year>2015</year><month>Oct</month><day>1</day>;<volume>526</volume>(<issue>7571</issue>):<fpage>68</fpage>–<lpage>74</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature15393</pub-id><?supplied-pmid 26432245?><pub-id pub-id-type="pmid">26432245</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref070">
      <label>70</label>
      <mixed-citation publication-type="journal"><name><surname>Karczewski</surname><given-names>KJ</given-names></name>, <name><surname>Francioli</surname><given-names>LC</given-names></name>, <name><surname>Tiao</surname><given-names>G</given-names></name>, <name><surname>Cummings</surname><given-names>BB</given-names></name>, <name><surname>Alföldi</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title>. <source>Nature</source>. <year>2020</year><month>May</month>;<volume>581</volume>(<issue>7809</issue>):<fpage>434</fpage>–<lpage>43</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2308-7</pub-id><?supplied-pmid 32461654?><pub-id pub-id-type="pmid">32461654</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref071">
      <label>71</label>
      <mixed-citation publication-type="journal"><name><surname>Tian</surname><given-names>L</given-names></name>, <name><surname>Shao</surname><given-names>Y</given-names></name>, <name><surname>Nance</surname><given-names>S</given-names></name>, <name><surname>Dang</surname><given-names>J</given-names></name>, <name><surname>Xu</surname><given-names>B</given-names></name>, <name><surname>Ma</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Long-read sequencing unveils IGH-DUX4 translocation into the silenced IGH allele in B-cell acute lymphoblastic leukemia</article-title>. <source>Nat Commun</source>. <year>2019</year><month>Jun</month><day>26</day>;<volume>10</volume>(<issue>1</issue>):<fpage>2789</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-019-10637-8</pub-id><?supplied-pmid 31243274?><pub-id pub-id-type="pmid">31243274</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref072">
      <label>72</label>
      <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>McCastlain</surname><given-names>K</given-names></name>, <name><surname>Yoshihara</surname><given-names>H</given-names></name>, <name><surname>Xu</surname><given-names>B</given-names></name>, <name><surname>Chang</surname><given-names>Y</given-names></name>, <name><surname>Churchman</surname><given-names>ML</given-names></name>, <etal>et al</etal>. <article-title>Deregulation of DUX4 and ERG in acute lymphoblastic leukemia</article-title>. <source>Nat Genet</source>. <year>2016</year><month>Dec</month>;<volume>48</volume>(<issue>12</issue>):<fpage>1481</fpage>–<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ng.3691</pub-id><?supplied-pmid 27776115?><pub-id pub-id-type="pmid">27776115</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref073">
      <label>73</label>
      <mixed-citation publication-type="journal"><name><surname>Mullighan</surname><given-names>CG</given-names></name>. <article-title>How advanced are we in targeting novel subtypes of ALL?</article-title><source>Best Pract Res Clin Haematol.</source><year>2019</year><source>Dec</source>;<volume>32</volume>(<issue>4</issue>):<fpage>101095</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.beha.2019.101095</pub-id><?supplied-pmid 31779973?><pub-id pub-id-type="pmid">31779973</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref074">
      <label>74</label>
      <mixed-citation publication-type="journal"><name><surname>Heldenbrand</surname><given-names>JR</given-names></name>, <name><surname>Baheti</surname><given-names>S</given-names></name>, <name><surname>Bockol</surname><given-names>MA</given-names></name>, <name><surname>Drucker</surname><given-names>TM</given-names></name>, <name><surname>Hart</surname><given-names>SN</given-names></name>, <name><surname>Hudson</surname><given-names>ME</given-names></name>, <etal>et al</etal>. <article-title>Recommendations for performance optimizations when using GATK3.8 and GATK4</article-title>. <source>BMC Bioinformatics</source>. <year>2019</year><month>Nov</month><day>8</day>;<volume>20</volume>(<issue>1</issue>):<fpage>557</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12859-019-3169-7</pub-id><?supplied-pmid 31703611?><pub-id pub-id-type="pmid">31703611</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref075">
      <label>75</label>
      <mixed-citation publication-type="journal"><name><surname>Coudray</surname><given-names>A</given-names></name>, <name><surname>Battenhouse</surname><given-names>AM</given-names></name>, <name><surname>Bucher</surname><given-names>P</given-names></name>, <name><surname>Iyer</surname><given-names>VR</given-names></name>. <article-title>Detection and benchmarking of somatic mutations in cancer genomes using RNA-seq data</article-title>. <source>PeerJ</source>. <year>2018</year><month>Jul</month><day>31</day>;<volume>6</volume>:<fpage>e5362</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7717/peerj.5362</pub-id><?supplied-pmid 30083469?><pub-id pub-id-type="pmid">30083469</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref076">
      <label>76</label>
      <mixed-citation publication-type="journal"><name><surname>Jia</surname><given-names>Y</given-names></name>, <name><surname>Xie</surname><given-names>Z</given-names></name>, <name><surname>Li</surname><given-names>H</given-names></name>. <article-title>Intergenically Spliced Chimeric RNAs in Cancer.</article-title><source>Trends Cancer Res</source>. <year>2016</year><month>Sep</month>;<volume>2</volume>(<issue>9</issue>):<fpage>475</fpage>–<lpage>84</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.trecan.2016.07.006</pub-id><?supplied-pmid 28210711?><pub-id pub-id-type="pmid">28210711</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref077">
      <label>77</label>
      <mixed-citation publication-type="journal"><name><surname>Lilljebjörn</surname><given-names>H</given-names></name>, <name><surname>Fioretos</surname><given-names>T</given-names></name>. <article-title>New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia</article-title>. <source>Blood</source>. <year>2017</year><month>Sep</month><day>21</day>;<volume>130</volume>(<issue>12</issue>):<fpage>1395</fpage>–<lpage>401</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood-2017-05-742643</pub-id><?supplied-pmid 28778863?><pub-id pub-id-type="pmid">28778863</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref078">
      <label>78</label>
      <mixed-citation publication-type="journal"><name><surname>Tavakoli Shirazi</surname><given-names>P</given-names></name>, <name><surname>Eadie</surname><given-names>LN</given-names></name>, <name><surname>Heatley</surname><given-names>SL</given-names></name>, <name><surname>Hughes</surname><given-names>TP</given-names></name>, <name><surname>Yeung</surname><given-names>DT</given-names></name>, <name><surname>White</surname><given-names>DL</given-names></name>. <article-title>The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.</article-title><source>Br J Cancer</source>. <year>2020</year><month>Feb</month>;<volume>122</volume>(<issue>4</issue>):<fpage>455</fpage>–<lpage>64</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41416-019-0647-7</pub-id><?supplied-pmid 31792348?><pub-id pub-id-type="pmid">31792348</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref079">
      <label>79</label>
      <mixed-citation publication-type="journal"><name><surname>Spinella</surname><given-names>J-F</given-names></name>, <name><surname>Cassart</surname><given-names>P</given-names></name>, <name><surname>Richer</surname><given-names>C</given-names></name>, <name><surname>Saillour</surname><given-names>V</given-names></name>, <name><surname>Ouimet</surname><given-names>M</given-names></name>, <name><surname>Langlois</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations</article-title>. <source>Oncotarget</source>. <year>2016</year><month>Oct</month><day>4</day>;<volume>7</volume>(<issue>40</issue>):<fpage>65485</fpage>–<lpage>503</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.18632/oncotarget.11796</pub-id><?supplied-pmid 27602765?><pub-id pub-id-type="pmid">27602765</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref080">
      <label>80</label>
      <mixed-citation publication-type="journal"><name><surname>Dobin</surname><given-names>A</given-names></name>, <name><surname>Davis</surname><given-names>CA</given-names></name>, <name><surname>Schlesinger</surname><given-names>F</given-names></name>, <name><surname>Drenkow</surname><given-names>J</given-names></name>, <name><surname>Zaleski</surname><given-names>C</given-names></name>, <name><surname>Jha</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source>. <year>2013</year><month>Jan</month><day>1</day>;<volume>29</volume>(<issue>1</issue>):<fpage>15</fpage>–<lpage>21</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><?supplied-pmid 23104886?><pub-id pub-id-type="pmid">23104886</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref081">
      <label>81</label>
      <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>K</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>Hakonarson</surname><given-names>H</given-names></name>. <article-title>ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data</article-title>. <source>Nucleic Acids Res</source>. <year>2010</year><month>Sep</month>;<volume>38</volume>(<issue>16</issue>):<fpage>e164</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkq603</pub-id><?supplied-pmid 20601685?><pub-id pub-id-type="pmid">20601685</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref082">
      <label>82</label>
      <mixed-citation publication-type="journal"><name><surname>Robinson</surname><given-names>JT</given-names></name>, <name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name>, <name><surname>Winckler</surname><given-names>W</given-names></name>, <name><surname>Guttman</surname><given-names>M</given-names></name>, <name><surname>Lander</surname><given-names>ES</given-names></name>, <name><surname>Getz</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Integrative genomics viewer</article-title>. <source>Nat Biotechnol</source>. <year>2011</year><month>Jan</month>;<volume>29</volume>(<issue>1</issue>):<fpage>24</fpage>–<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nbt.1754</pub-id><?supplied-pmid 21221095?><pub-id pub-id-type="pmid">21221095</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref083">
      <label>83</label>
      <mixed-citation publication-type="journal"><name><surname>Liao</surname><given-names>Y</given-names></name>, <name><surname>Smyth</surname><given-names>GK</given-names></name>, <name><surname>Shi</surname><given-names>W</given-names></name>. <article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title>. <source>Bioinformatics</source>. <year>2014</year><month>Apr</month><day>1</day>;<volume>30</volume>(<issue>7</issue>):<fpage>923</fpage>–<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><?supplied-pmid 24227677?><pub-id pub-id-type="pmid">24227677</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref084">
      <label>84</label>
      <mixed-citation publication-type="journal"><name><surname>Robinson</surname><given-names>MD</given-names></name>, <name><surname>McCarthy</surname><given-names>DJ</given-names></name>, <name><surname>Smyth</surname><given-names>GK</given-names></name>. <article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title>. <source>Bioinformatics</source>. <year>2010</year><month>Jan</month><day>1</day>;<volume>26</volume>(<issue>1</issue>):<fpage>139</fpage>–<lpage>40</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><?supplied-pmid 19910308?><pub-id pub-id-type="pmid">19910308</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref085">
      <label>85</label>
      <mixed-citation publication-type="journal"><name><surname>Yeoh</surname><given-names>E-J</given-names></name>, <name><surname>Ross</surname><given-names>ME</given-names></name>, <name><surname>Shurtleff</surname><given-names>SA</given-names></name>, <name><surname>Williams</surname><given-names>WK</given-names></name>, <name><surname>Patel</surname><given-names>D</given-names></name>, <name><surname>Mahfouz</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling</article-title>. <source>Cancer Cell</source>. <year>2002</year><month>Mar</month>;<volume>1</volume>(<issue>2</issue>):<fpage>133</fpage>–<lpage>43</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s1535-6108(02)00032-6</pub-id><?supplied-pmid 12086872?><pub-id pub-id-type="pmid">12086872</pub-id></mixed-citation>
    </ref>
    <ref id="pgen.1010300.ref086">
      <label>86</label>
      <mixed-citation publication-type="journal"><name><surname>Harvey</surname><given-names>RC</given-names></name>, <name><surname>Mullighan</surname><given-names>CG</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Dobbin</surname><given-names>KK</given-names></name>, <name><surname>Davidson</surname><given-names>GS</given-names></name>, <name><surname>Bedrick</surname><given-names>EJ</given-names></name>, <etal>et al</etal>. <article-title>Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.</article-title><source>Blood</source>. <year>2010</year><month>Dec</month><day>2</day>;<volume>116</volume>(<issue>23</issue>):<fpage>4874</fpage>–<lpage>84</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood-2009-08-239681</pub-id><?supplied-pmid 20699438?><pub-id pub-id-type="pmid">20699438</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pgen.1010300.r001" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pgen.1010300.r001</article-id>
    <title-group>
      <article-title>Decision Letter 0</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>McKinnon</surname>
          <given-names>Peter</given-names>
        </name>
        <role>Section Editor: Cancer Genetics</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gartenhaus</surname>
          <given-names>Ronald B</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2022 McKinnon, Gartenhaus</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>McKinnon, Gartenhaus</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pgen.1010300" id="rel-obj001" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>0</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">25 Jul 2022</named-content>
    </p>
    <p>Dear Dr Breen,</p>
    <p>Thank you very much for submitting your Research Article entitled 'RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)' to PLOS Genetics.</p>
    <p>The manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the current manuscript. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review a much-revised version. We cannot, of course, promise publication at that time.</p>
    <p>Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer especially reviewer # 2. Importantly, please address the overarching concern, regarding "what is the real need in a clinical/diagnostic lab and whether such labs will use such a pipeline".  We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.</p>
    <p>If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to <email>plosgenetics@plos.org</email>.</p>
    <p>If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our <ext-link xlink:href="http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist" ext-link-type="uri">Submission Checklist</ext-link>.</p>
    <p>To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link></p>
    <p>Please be aware that our <ext-link xlink:href="http://journals.plos.org/plosgenetics/s/data-availability" ext-link-type="uri">data availability policy</ext-link> requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.</p>
    <p>While revising your submission, please upload your figure files to the <ext-link xlink:href="http://pace.apexcovantage.com/" ext-link-type="uri">Preflight Analysis and Conversion Engine</ext-link> (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <email>figures@plos.org</email>.</p>
    <p>PLOS has incorporated <ext-link xlink:href="http://www.crossref.org/crosscheck.html" ext-link-type="uri">Similarity Check</ext-link>, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.</p>
    <p>To resubmit, use the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.</p>
    <p>[LINK]</p>
    <p>We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.</p>
    <p>Yours sincerely,</p>
    <p>Ronald B Gartenhaus</p>
    <p>Academic Editor</p>
    <p>PLOS Genetics</p>
    <p>Peter McKinnon</p>
    <p>Section Editor: Cancer Genetics</p>
    <p>PLOS Genetics</p>
    <p>Reviewer's Responses to Questions</p>
    <p>
      <bold>Comments to the Authors:</bold>
    </p>
    <p>
      <bold>Please note here if the review is uploaded as an attachment.</bold>
    </p>
    <p>Reviewer #1: With this manuscript the authors describe a novel computational algorithm to identify genomic alterations that define subtypes of acute lymphoblastic leukemia from RNA sequencing. The approach uses the k-mer based targeted detection tool and known sets of ALL variants and was compared to standard alignment based pipelines. The tool appears to perform relatively well, particularly in identifying difficult to detect variants in the test cohort and a validation cohort. The approach may have some advantages in terms of required computational resources and time.</p>
    <p>This is a potentially useful tool that appears to perform well. A disadvantage is that novel fusions may be missed as the algorithm depends on prior knowledge of variant sequences. This disadvantage is mitigated with the ability to add target sequences when they are reported. What is not discussed is how this algorithm might be implemented clinically, particularly in light of regulatory oversight of laboratory generated data that may be used for clinical decision making.</p>
    <p>Reviewer #2: In this study, authors introduce a computational pipeline, RaScALL, for inferring genomic aberrations from RNA-sequencing data in ALL patients. RaScALL pipeline allows for screening and inferring gene fusions, SNVs and focal gene deletions with potential prognostic value for ALL patients. Moreover, RaScALL implements the km algorithm that conducts a pseudo-alignment rather than a direct mapping of raw RNA-seq reads to a reference genome. Authors argue that this approach is more efficient in terms of memory and computational time as it reduces the search space.</p>
    <p>The workflow of RaScALL includes implementation of four fusion calling algorithms (FusionCatcher, SOAPfuse, JAFFA and Arriba), and the consensus of at least two of the algorithms was required for gene fusion identification (except for IGH rearrangements, IGHr).</p>
    <p>Authors applied RaScALL in a patient cohort of 180 subjects that represent common prognostic genomic lesions in B-ALL (160), T-ALL (18) and mixed lineage leukaemia, MLL (2). They also validated RaScALL inferences via the data analysis of 100 publicly available datasets samples.</p>
    <p>The results show that RaScALL successfully identified gene fusions in both cohorts for a fraction of computational time. Their pipeline can accommodate new reports of gene fusions and de novo variants.</p>
    <p>I find this paper of great-quality work that makes a contribution to cancer research. Authors present a new computational tool that can benefit the clinicians for disease diagnosis in ALL patients. However, the first big question is what is the real need in a clinical/diagnostic lab and whether such labs will use such a pipeline. Let’s not forget that RNA-Seq is not used routinely for diagnostics on ALL. It is used infrequently, for example in cases that are suspected Ph-like and in most laboratories, samples are sent out for RNA-Seq to reference laboratories. Most places are probably not even sending out such samples. Apart from this general comment, there are several issues that need to be addressed:</p>
    <p>• The T-ALL cohort is small and key mutations (NOTCH1, FBXW7, PTEN etc) and not ever represented. The authors should expand the cohort and add such mutations and also ad additional events (MYC duplications, NOTCH rearrangements etc).</p>
    <p>• How easy is to modify RaScALL? Add mutations, rearrangements etc? How that would affect the analysis time and flow?</p>
    <p>• What is the cost of running RaScALL per sample?</p>
    <p>• Lines 132-134: Add the citation of the km algorithm.</p>
    <p>• Lines 156-161: There are some inconsistencies here when describing the study cohort. E.g., You have merged the ALL, MLL patients for the data analysis as I can see in the Methods section and Figure 1. But this is not clear here. You should also explain here that there was a validation cohort, different ALL subtypes etc</p>
    <p>• Figure1: It would be interesting to see how the identification of genetic fusions change in ALL patients in different disease stages (patients at Diagnosis vs Relapse disease stages). Are there any differences? Maybe consider to add the time point here? Also, you should include here the results from the study and validation cohorts together.</p>
    <p>• Line 169: You need to explain why IGHr were excluded. It seems that this is explained later as “regions with highly variable breakpoint locations” (Line 197). But you should elaborate more on this, and add a citation.</p>
    <p>• Lines 171-172 and Lines 397-398: You mention that your study cohort contained patient of high sequencing coverage (mean 70M PE reads). How is the performance of RaScALL affected by the read coverage? Provide minimum read coverage or suggestions for the user to deal with such patient cases.</p>
    <p>• Line 189: are the identified pathogenic SNVs first-time reported here (thanks to RaScALL) or are these based on known SNVs?</p>
    <p>• Lines 250-251: This information is partially stated as part of the beginning in the Results section (Lines 156-160); consider merging these two parts.</p>
    <p>• Line 304: To add citation about MLPA analysis.</p>
    <p>• Line 326: Caption should be more self-explanatory. E.g., explain a little bit what MLPA analysis is. Are the results here related to the detection of IKZF1 intragenic deletions by using RaScALL and comparing them to the MLPA analysis?</p>
    <p>• Line 385, Figure 4: You should show the overall performance, accuracy and run time of RaScALL pipeline comparing to the other methods (FusionCatcher, SOAPfuse, JAFFA and Arriba), and how these change as you get concordance from 2, 3 or all 4 methods.</p>
    <p>• Lines 430-431: Maybe, it would be useful for researchers/clinicians to get a prognostic risk score or a label that would indicate ALL subtype and/or disease stage based on the identification of the genetic lesions, that would help patient stratification and indicate progression of the disease.</p>
    <p>**********</p>
    <p>
      <bold>Have all data underlying the figures and results presented in the manuscript been provided?</bold>
    </p>
    <p>Large-scale datasets should be made available via a public repository as described in the <italic toggle="yes">PLOS Genetics</italic>
<ext-link xlink:href="http://journals.plos.org/plosgenetics/s/data-availability" ext-link-type="uri">data availability policy</ext-link>, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.</p>
    <p>Reviewer #1: Yes</p>
    <p>Reviewer #2: Yes</p>
    <p>**********</p>
    <p>PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
    <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
    <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p>
    <p>Reviewer #1: No</p>
    <p>Reviewer #2: No</p>
  </body>
</sub-article>
<sub-article article-type="author-comment" id="pgen.1010300.r002">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pgen.1010300.r002</article-id>
    <title-group>
      <article-title>Author response to Decision Letter 0</article-title>
    </title-group>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pgen.1010300" id="rel-obj002" related-article-type="editor-report"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="author-response-date">22 Sep 2022</named-content>
    </p>
    <supplementary-material id="pgen.1010300.s011" position="float" content-type="local-data">
      <label>Attachment</label>
      <caption>
        <p>Submitted filename: <named-content content-type="submitted-filename">Response_for_reviewers.docx</named-content></p>
      </caption>
      <media xlink:href="pgen.1010300.s011.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </body>
</sub-article>
<sub-article article-type="editor-report" id="pgen.1010300.r003" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pgen.1010300.r003</article-id>
    <title-group>
      <article-title>Decision Letter 1</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>McKinnon</surname>
          <given-names>Peter</given-names>
        </name>
        <role>Section Editor</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gartenhaus</surname>
          <given-names>Ronald B</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2022 McKinnon, Gartenhaus</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>McKinnon, Gartenhaus</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pgen.1010300" id="rel-obj003" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">22 Sep 2022</named-content>
    </p>
    <p>Dear Dr Breen,</p>
    <p>We are pleased to inform you that your manuscript entitled "RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)" has been editorially accepted for publication in PLOS Genetics. Congratulations!</p>
    <p>Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional acceptance, but your manuscript will not be scheduled for publication until the required changes have been made.</p>
    <p>Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you’ve already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <email>plosgenetics@plos.org</email>.</p>
    <p>In the meantime, please log into Editorial Manager at <ext-link xlink:href="https://www.editorialmanager.com/pgenetics/" ext-link-type="uri">https://www.editorialmanager.com/pgenetics/</ext-link>, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.</p>
    <p>If you have a press-related query, or would like to know about making your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.</p>
    <p>Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!</p>
    <p>Yours sincerely,</p>
    <p>Ronald B Gartenhaus</p>
    <p>Academic Editor</p>
    <p>PLOS Genetics</p>
    <p>Peter McKinnon</p>
    <p>Section Editor</p>
    <p>PLOS Genetics</p>
    <p>
      <ext-link xlink:href="http://www.plosgenetics.org" ext-link-type="uri">www.plosgenetics.org</ext-link>
    </p>
    <p>Twitter: @PLOSGenetics</p>
    <p>----------------------------------------------------</p>
    <p>Comments from the reviewers (if applicable):</p>
    <p>----------------------------------------------------</p>
    <p>
      <bold>Data Deposition</bold>
    </p>
    <p>If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the <ext-link xlink:href="http://www.datadryad.org/" ext-link-type="uri">Dryad Digital Repository</ext-link>. As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our <ext-link xlink:href="http://journals.plos.org/plosgenetics/s/data-availability#loc-recommended-repositories" ext-link-type="uri">website</ext-link>.</p>
    <p>The following link will take you to the Dryad record for your article, so you won't have to re‐enter its bibliographic information, and can upload your files directly: </p>
    <p>
      <ext-link xlink:href="http://datadryad.org/submit?journalID=pgenetics&amp;manu=PGENETICS-D-22-00730R1" ext-link-type="uri">http://datadryad.org/submit?journalID=pgenetics&amp;manu=PGENETICS-D-22-00730R1</ext-link>
    </p>
    <p>More information about depositing data in Dryad is available at <ext-link xlink:href="http://www.datadryad.org/depositing" ext-link-type="uri">http://www.datadryad.org/depositing</ext-link>. If you experience any difficulties in submitting your data, please contact <email>help@datadryad.org</email> for support.</p>
    <p>Additionally, please be aware that our <ext-link xlink:href="http://journals.plos.org/plosgenetics/s/data-availability" ext-link-type="uri">data availability policy</ext-link> requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.</p>
    <p>----------------------------------------------------</p>
    <p>
      <bold>Press Queries</bold>
    </p>
    <p>If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper's publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there's anything the journal should know or you'd like more information, please get in touch via <email>plosgenetics@plos.org</email>.</p>
  </body>
</sub-article>
<sub-article article-type="editor-report" id="pgen.1010300.r004" specific-use="acceptance-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pgen.1010300.r004</article-id>
    <title-group>
      <article-title>Acceptance letter</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>McKinnon</surname>
          <given-names>Peter</given-names>
        </name>
        <role>Section Editor</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gartenhaus</surname>
          <given-names>Ronald B</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2022 McKinnon, Gartenhaus</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>McKinnon, Gartenhaus</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pgen.1010300" id="rel-obj004" related-article-type="reviewed-article"/>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">12 Oct 2022</named-content>
    </p>
    <p>PGENETICS-D-22-00730R1 </p>
    <p>RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL) </p>
    <p>Dear Dr Breen, </p>
    <p>We are pleased to inform you that your manuscript entitled "RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.</p>
    <p>The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. </p>
    <p>Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.</p>
    <p>Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work! </p>
    <p>With kind regards,</p>
    <p>Anita Estes</p>
    <p>PLOS Genetics</p>
    <p>On behalf of:</p>
    <p>The PLOS Genetics Team</p>
    <p>Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom</p>
    <p><email>plosgenetics@plos.org</email> | +44 (0) 1223-442823</p>
    <p><ext-link xlink:href="http://plosgenetics.org" ext-link-type="uri">plosgenetics.org</ext-link> | Twitter: @PLOSGenetics</p>
  </body>
</sub-article>
